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3ABSTRACT 
Eye diseases characterized by excessive angiogenesis such as wet age2related 
macular degeneration, proliferative diabetic retinopathy, and retinopathy of 
prematurity are major causes of blindness. Cremastranone is an anti2angiogenic, 
naturally occurring homoisoflavanone with efficacy in retinal and choroidal 
neovascularization models and antiproliferative selectivity for endothelial cells 
over other cell types. We undertook a cell-based structure2activity relationship 
study to develop more potent cremastranone analogs, with improved 
antiproliferative selectivity for retinal endothelial cells. Phenylalanyl2incorporated 
homoisoflavonoids showed improved activity and remarkable selectivity for retinal 
microvascular endothelial cells. A lead compound inhibited angiogenesis in vitro 
without inducing apoptosis, and had efficacy in the oxygen2induced retinopathy 
model in vivo. 
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dimethyl acetal, followed by catalytic hydrogenation of the resulting 42chromenes 
to afford chroman242ones (6a~6c), respectively. Among them, 6a was treated with 
isovanillin and p2TsOH, followed by catalytic hydrogenation to afford the resulting 
homoisoflavanone 8. Finally the treatment of 8 with TMSI gave cremastranone (1) 
with improved yield and reaction steps. In a similar manner, 2 as well as 
homoisoflavanone 9 were prepared from 6b which was converted into 
homoisoflavanone 10 before TMSI demethylation. Also, homoisoflavanone 11 was 
synthesized from 6c in 2 steps.  
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Scheme 1. Synthesis of Cremastranone and Its A2ring Modified Analogs via 
Chroman242ones. 
 
Reagents and conditions: (i) (CH3)2NCH(OCH3)2, toluene, reflux (82~97%); (ii) H2, 
Pd/C, MeOH, rt (87~99%); (iii) isovanillin, p2TsOH, benzene, reflux (60~77%); 
(iv) TMSI, CHCl3, 60 °C (45~83%). 
Synthesis of B-ring Modified Homoisoflavanones. To prepare 
homoisoflavanones modified on the B ring, 32benzylidene242chromanones 7d and 
7e were prepared from 7b by treatment with benzyl bromide and allyl bromide. 
Aldol condensation of 5,6,72trimethoxy242chromanone (6b) with the appropriate 
arylaldehydes under acidic conditions gave the other 32benzylidene242
chromanones (7f~7r) (Scheme 2 and Supplementary Scheme 1). As previously 
described, 32benzyl25,6,72trimethoxychroman242one (12a) was prepared from 
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3,4,52trimethoxyphenol (Supplementary Scheme 2).7,19 Catalytic hydrogenation of 
32benzylidene242chromanones 7f and 7g gave 12b and 12c which were hydrolyzed 
to 12d and 10 was transformed to the benzylated and acylated 32benzyl242
chromanones 12f~12i.  
Scheme 2. Synthesis of B Ring2Modified Homoisoflavonoids (7d~7l and 
12a~12i). 
7b
7d (R=OBn)
7e (R=OAllyl)
O
MeO
MeO
MeO
O
i R
OMe
6b
7f
7g
7h
7i
7j
7k
7l
O
MeO
MeO
MeO
O
ii
R1
R2
O
MeO
MeO
MeO
O
12a
OH
MeO
MeO
MeO
iii-v
12e
12f
12g
12h
12i
O
MeO
MeO
MeO
O
10
iv
vi
12b (R=NH2)
12c (R=CO2Me)
12d (R=CO2H)
O
MeO
MeO
MeO
O
R
OMe
i R
OMe
iv
vii or
viii
(R=OBn)
(R=OBz)
(R=OCOCH=CHPh)
(R=OCOCH2-CH2Ph)
(R=OCONEt2)
(R1=NO2, R2=OMe)
(R1=CO2Me, R2=OMe)
(R1=F, R2=OMe)
(R1=OMe, R2=OH)
(R1=OMe, R2=OBn)
(R1=OH, R2=OH)
(R1=OBn, R2=OBn)
Reagents and conditions: (i) benzyl bromide or allyl bromide, K2CO3, acetone (79% 
for 7d, 83% for 7e and 84% for 12e); (ii) arylaldehydes, p2TsOH, benzene, reflux 
(59~87%); (iii) cinnamoyl chloride, BF3·Et2O, reflux (98%); (iv) H2, Pd/C, MeOH, 
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rt (96%); (v) aq. HCHO, NaOH, 60 °C (43%); (vi) LiOH, H2O, THF (56%); (vii), 
benzoyl chloride or cinnamoyl chloride, acetone (82% for 12f and 80% for 12g); 
(viii) ClCONEt2, Et3N, toluene, reflux (40%). 
As shown in Scheme 3, to improve the biological activity along with druglike 
properties, several amino acids functionalized on the NH2 group such as 
carbamate, urea and sulfonamide were introduced on the C3′ position of 10 via 
EDCI2mediated coupling to afford aryl ester analogs (14a~14j). Similar to 
14a~14c, amine 12b was coupled with the N2substituted amino acids to afford the 
N2arylamide analogs (15a~15c).  
Scheme 3. Synthesis of Homoisoflavonoids (14a~14j and 15a~15c) Comprising 
Amino Acids on the C3′ Position of the B2Ring. 
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Reagents and conditions: (i) N2substituted amino acids, EDCI (or DCC), DMAP, 
CH2Cl2, rt (42~92%). 
Biological Evaluation of A-ring Modified Homoisoflavanones. In the 
homoisoflavanone series modified on the A ring, the majority of synthetic 
compounds except cremastranone exhibited weak inhibitory activity of cell 
proliferation and poor selectivity for human microvascular retinal endothelial cells 
(HRECs) compared to HUVECs and human ocular tumor cell lines 9221 (uveal 
melanoma) and Y79 (retinoblastoma) (Table 1). Cremastranone 1 showed potent 
inhibitory activity of HREC and HUVEC proliferation, as reported already,5 
whereas regioisomers with the different site2combinations of hydroxy and methoxy 
groups on the A ring had lower activity than the natural compound. Compounds 8 
and 9 lost the inhibitory activity on HREC cell proliferation, while 
homoisoflavanones 10 and 11 functionalized only with methoxy groups had good 
activity. Although compound 10 with trimethoxy on C5, C6 and C7 did not show 
stronger activity than cremastranone, it did show good selectivity for HRECs over 
other cell types including HUVECs. Thus, it was chosen as the starting point for 
further analogs in order to discover potent, microvascular endothelial2cell specific, 
antiangiogenic agents and to expand chemical space.  
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Table 1. Growth Inhibitory Activity (GI50, SM) of A2ring Modified 
Homoisoflavanones on the Proliferation of Microvascular (HREC), Macrovascular 
(HUVEC) and Ocular Tumor (9221 and Y79) Cells. 95% Confidence Interval 
Shown in Parentheses. 
 
Cpd A ring HREC HUVEC 9221 Y79 
1 
 
0.22 
(0.12 – 0.39) 
0.38 
(0.24 – 0.59) 
48 
(17 – 132) 
9.8 
(2.1 – 45) 
2 
 
45 
(26 – 75) 
18 
(16 – 21) 
10 
(4.4 – 23) 
>100 
8 
 
>100 >100 >100 >100 
9 
 
>100 44 
(34 – 58) 
>100 >100 
10 
 
2 
(0.81 – 5.1) 
12 
(2.7 – 55) 
>100 >100 
11 
 
1.6 
(1.0 – 2.6) 
2.5 
(0.87 – 7.1) 
>100 4.2 
(2.0 – 9.1) 
 
Biological Evaluation of B-ring Modified Homoisoflavanones. In a series of 
homoisoflavanones modified on the B ring, 32benzylidene242chromanones with 
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mono2substituents on C2′ and C4′, di2substituents on C2′/C3′ and C3′/C4′, and 
trimethoxy groups on C2′/C3′/C4′ and C3′/C4′/C5′ of the B ring were evaluated 
(Table 2 and Supplementary Table 1). Compared to the 32benzyl242chromanones 
10 and 11, 32benzylidene242chromanones 7b and 7c did not exhibit satisfactory 
activity against HRECs nor selectivity. On the other hand, 32(3′,4′2disubstituted2
benzylidene)242chromanones (7d~7h) with a methoxy group at the C4′ position 
had moderate anti2proliferative activity (GI50  3~6 SM for HRECs), although still 
lacked selectivity. 32Benzylidene242chromanones substituted on either C2′ or C4′ 
and those with a trimethoxy substituent on C2′/C3′/C4′ and C3′/C4′/C5′ had 
substantially decreased inhibitory activity on HREC proliferation (Supplementary 
Table 1). Additionally, the bulkier benzyl group at the C4 position led to lower 
activity than the hydroxyl or methoxy group (7i vs 7j, 7k vs 7l). 
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Table 2. Growth Inhibitory Activity (GI50, SM) of B2ring Modified 32Benzylidene2
42chromanone Analogs. 95% Confidence Interval Shown in Parentheses. 
 
Cpd B ring HREC HUVEC 9221 Y79 
7b 
 
46 
(17 – 122) 
5.6 
(3.2 – 9.8) 
0.22 
(0.061 – 
0.81) 
44 
(22 – 89) 
7c
a
 
 
42 
(12 – 146) 
15 
(4.4 – 51) 
>100 
 
14 
(7.2 – 25) 
7d 
 
4.3 
(1.9 – 9.7) 
16 
(5.2 – 49) 
3.5 
(1.4 – 9.0) 
33 
(6.1 – 180) 
7e  
 
3.9 
(1.9 – 8.1) 
12 
(7.6 – 18) 
1.1 
(0.34 – 3.6) 
2.8 
(1.5 – 5.1) 
7f  
 
4.8 
(2.2 – 11) 
15 
(7.2 – 31) 
12 
(6.5 – 24) 
2.2 
(0.72 – 6.4) 
7g  
 
5.6 
(2.6 – 12) 
3.2 
(1.4 – 7.3) 
>100 6.1 
(3.4 – 11) 
7h 
 
2.8 
(1.1 – 7.1) 
7.6 
(3.2 – 18) 
7.0 
(1.9 – 26) 
9.8 
(4.1 – 23) 
7i  
 
3.3 
(1.7 – 6.4) 
6.2 
(5.1 – 7.7) 
26 
(8.6 – 77) 
5.2 
(3.2 – 8.2) 
7j  
 
35 
(14 – 83) 
52 
(27 – 100) 
68 
(25 – 186) 
14 
(8.7 – 24) 
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7k  
 
7.6 
(2.7 – 22) 
5.0 
(2.2 – 11) 
9.5 
(4.8 – 19) 
4.0 
(0.86 – 19 
7l  
 
72 
(18 – 277 
43 
(9.1 – 204 
>100 32 
(12 – 88) 
a. 32(3′2hydroxy24′2methoxybenzylidene)25,72dimethoxychroman242one 
In contrast to the 32benzylidene242chromanones with a planar conformation, the 
freedom of rotation of 32benzyl242chromanones might affect the selectivity for 
HRECs over human ocular tumor cell lines (Table 3). Mainly 32benzyl242
chromanones bearing methoxy on C4′ of the B ring were evaluated along with 12a, 
which shows little antiproliferative activity. Aniline 12b showed excellent 
antiproliferative activity, but ester 12c and acid 12d showed little or no 
antiproliferative activity. Benzyl (12e) and carbamoyl (12i) compounds were found 
to be weak growth inhibitors. Interestingly, introduction of acyl groups such as 
benzoyl (12f), cinnamoyl (12g) and dihydrocinnamoyl (12h) strongly increased 
activity with GI50 values of 0.14~0.65 SM for HRECs. Moreover 12f~12h were 
selective for HREC inhibition over HUVECs, Y79, and 9221 cells. The 
antiproliferative activities were obviously dependent on the substitution pattern of 
the B ring. 
Table 3. Growth Inhibitory Activity (GI50, SM) of B2ring Modified 32Benzyl242
chromanone Analogs. 95% Confidence Interval Shown in Parentheses. 
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Cpd B ring HREC HUVEC 9221 Y79 
12a  
 
>100 >100 >100 >100 
12b 
 
1.1 
(0.29 – 
4.4) 
0.51 
(0.11 – 
25) 
>100 >100 
12c 
 
18 
(6.1 – 50) 
17 
(5.1 – 57) 
>100 40 
(24 – 66) 
12d 
 
>100 92 
(27 – 317) 
>100 >100 
12e  
 
22 
(13 – 40) 
>100 61 
(14 – 278) 
20 
(8.1 – 51) 
12f 
 
0.65 
(0.26 – 
1.6) 
>100 >100 
 
>100 
12g 
 
0.17 
(0.030 – 
0.97) 
>100 >100 >100 
12h  
 
0.22 
(0.064 – 
0.77) 
38 
(13 – 109) 
>100 >100 
12i  
 
49 
(17 – 141) 
>100 >100 24 
(6.1 – 97) 
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Biological Evaluation of Homoisoflavanones Coupled with Amino Acids on 
the C3′ position. Encouraged by the potent activity of aryl esters (12f~12h), 
phenol 10 and aniline 12b were coupled with some N2protected amino acids to 
obtain the ester (14a~14j) and amide (15a-15c) analogs, respectively. Interestingly, 
14a which was given by coupling 10 with Boc2Phe2OH showed the most potent 
activity with GI50 = 55 nM against HRECs (Table 4; Figure 2A). Moreover 14a 
selectively inhibited HREC proliferation about 142fold over HUVECs, 2182fold 
over Y79, and >10002fold over 9221, suggestive of cytostatic effects on HRECs 
rather than general cytotoxicity. The analogs (14b and 14c) for which 10 was 
coupled with Boc2Tyr(Bn)2OH and Boc2Tyr(Allyl)2OH had similar activity to 14a, 
potentially indicating that a bulkier (or longer) chemical spacer to the phenyl ring 
of the phenylalaninyl moiety is not detrimental to potency. An isoleucinyl analog 
(14d) had lower antiproliferative activity, whereas analogs (14e, 14f and 14g) 
generated with Boc2Leu2OH, Boc2homophe2OH and Cbz2Phe2OH have more 
preferable activity and selectivity to cremastranone. The antiproliferative activity 
of ethylurea (14h), butylurea (14i) and sulfonamide (14j) analogs was not 
improved. Noteworthy, the inhibition of HREC proliferation with N2arylamide 
analogs (15a~15c) decreased substantially, compared with the corresponding 
phenyl ester analogs (14a~14c). Conversely, N2arylaminde analogs were 
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considered to be moderate inhibitors against 9221 and/or Y79 cells rather than 
antiangiogenic compounds. 
Table 4. Growth Inhibitory Activity (GI50, SM) of Homoisoflavonoids Comprising 
Amino Acids on the C3′ Position of the B2Ring. 95% Confidence Interval Shown 
in Parentheses. 
 
Cpd B ring HREC HUVEC 9221 Y79 
14a  
 
0.055 
(0.032 – 
0.094) 
0.75 
(0.37 – 1.5) 
>100 12 
(5.7 – 25) 
14b 
 
0.51 
(0.26 – 1.0) 
>100 
 
>100 >100 
14c  
 
0.16 
(0.020 – 
1.3) 
0.091 
0.013) – 
0.63) 
>100 52 
17 – 166 
14d  
 
3.1 
(1.3 – 7.4) 
>100 >100 24 
(7.1 – 79) 
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14e  
 
0.13 
(0.026 – 
0.69) 
>100 >100 >100 
14f  
 
0.17 
(0.035 – 
0.82) 
>100 >100 >100 
14g  
 
0.14 
(0.027 – 
0.73) 
>100 >100 >100 
14h  
 
1.0 
(0.031 – 
3.6) 
34 
(7.2 –165 
 
98 
(37 – 265) 
48 
(33 – 69) 
 
14i 
 
1.4 
(0.73 – 2.4) 
>100 >100 64 
(26 –158) 
14j  
 
1.5 
(0.41 – 5.4) 
22 
(11 – 43) 
>100 
 
>100 
15a 
 
22 
(16 – 32) 
8.6 
(1.2 – 6.1) 
3.1 
(0.93 – 10) 
4.7 
(1.2 – 18) 
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15b  
 
>100 >100 >100 0.39 
(0.12 – 1.3) 
15c  
 
13 
(9.7 – 17) 
4.5 
(1.2 – 17) 
1.9 
(0.65 – 5.3) 
2.5 
(1.4 – 4.6) 
 
Validation of a Potent Cremastranone Derivative In Vitro: In alamarBlue 
proliferation assays, 14a had the highest potency of any compound tested. In 
addition, it was more potent and endothelial2cell specific than previously described 
antiangiogenic homoisoflavonoids.5, 11214 Given this, we tested it in a secondary cell 
proliferation assay, which monitors the incorporation of a thymidine analogue 52
ethynyl22′2deoxyuridine into DNA of proliferating HRECs. Here, we confirmed 
the dose2dependent inhibition of HREC proliferation by 14a, without any signs of 
apoptotic nuclear morphology (Supplementary Figure 1). 
After establishing the antiproliferative activity of this promising lead, we further 
tested its antiangiogenic activities in vitro. First we monitored the migration of 
HRECs, testing this important property of endothelial cells during blood vessel 
formation in the presence of 14a in a scratch wound assay (Figure 2B). 14a 
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blocked the ability of HRECs to migrate in a dose dependent manner. Then we 
tested the ability of HRECs to form tubes in the presence of 14a in a Matrigel tube 
formation assay, an in vitro assay that recapitulates most of the events of 
physiological angiogenesis such as migration, proliferation, and cell2cell adhesion. 
14a inhibited the tube formation ability of HRECs in the Matrigel assay at sub 
micromolar concentrations (Figure 2C).  
Although 14a did not induce changes in cell morphology in these assays, since 
the compound was so potent in inhibiting tube formation, we tested if 14a induces 
apoptosis in HRECs. We employed both activated caspase (Figure 2D) and 
TUNEL (Supplementary Figure 2) assays to monitor the apoptosis of HRECs in 
the presence of different concentrations of 14a. We observed less than 10% HREC 
cells undergoing apoptosis treated with up to 2 µM 14a, indicating that the 
compound may not be cytotoxic at effective concentrations. Furthermore, a trypan 
blue exclusion assay confirmed that treated HRECs retained viability 
(Supplementary Figure 3), further implicating a cytostatic rather than cytotoxic 
mechanism for this compound. This finding was further supported by analysis of 
the cell cycle profile in HRECs treated with 14a, which revealed a dose2dependent 
G2/M phase blockade with few sub2G0 cells (Supplementary Figure 4), as 
documented previously for cremastranone.10 These results established that 14a is a 
potent inhibitor of angiogenesis in vitro.  
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Figure 2. Compound 14a inhibits angiogenic behavior of HRECs in vitro. (A) 
Dose2response of the effects of 14a on HREC proliferation as measured by 
alamarBlue fluorescence. (B) 14a dose2dependently inhibits migration of HRECs 
in a scratch2wound assay. (C) 14a dose2dependently inhibits tube formation of 
HRECs on Matrigel. (D) 14a caused negligible apoptosis as assayed by activated 
caspase 3 (pink) immunofluorescence. 1 µM staurosporine (SP) is positive control. 
DAPI (blue) indicates normal nuclear morphology. Error bars indicate SEM, n=3, 
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representative results from at least triplicate experiments. *P<0.05, **P<0.01 and 
***P<0.001. Scale bars = 200 µm. 
In vivo efficacy of a Potent Cremastranone Derivative: After establishing 
antiangiogenic activity of 14a in vitro, we next explored the in vivo efficacy of this 
compound in preventing neovascularization in the OIR mouse model. Intravitreal 
injection of 14a to a final concentration of 1 µM in each eye significantly inhibited 
retinal neovascularization in OIR mice as compared to vehicle. Moreover, efficacy 
of the compound in vivo was similar to that observed with standard2of2care anti2
VEGF antibody treatment (Figure 3). We did not observe any overt systemic or 
ocular toxicity in mice treated with 14a, or gross morphological changes in the 
retinal vasculature. However, more extensive toxicological assessment of 14a 
remains to be done. 
The in vivo antiangiogenic activity of 14a observed here provides evidence that 
novel synthetic homoisoflavonoids that show potent and selective antiangiogenic 
activity in vitro can be used as lead molecules to develop drugs for treatment of 
ocular diseases arising from pathological angiogenesis. 
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Figure 3. Homoisoflavonoid 14a inhibits retinal neovascularization in the OIR 
mouse model. Retinal whole mounts from treated mice were stained for blood 
vessels using Alexa24882conjugated isolectin and imaged by confocal microscopy; 
neovascular area was measured using Adobe Photoshop. Error bars indicate SEM, 
n=6. **P<0.01. 
CONCLUSION 
We synthesized a series of homoisoflavonoids from chroman242ones, including 
successfully synthesizing the natural product cremastranone. Antiproliferative 
compounds with endothelial cell specificity, with a homoisoflavonoid2based 
scaffold, were developed as potent inhibitors of angiogenesis. The scaffold is 
sensitive to changes on the substituents on both the A and B rings. Exploring 
modification at the C3′ position revealed that addition of N2carbamate amino acids 
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improved inhibitory activity on HREC proliferation. The most potent 
phenylalanyl2incorporated 14a showed improved activity and remarkable 
selectivity for retinal microvascular endothelial cells, with antiangiogenic efficacy 
in vitro and in the oxygen2induced retinopathy model in vivo. 
EXPERIMENTAL SECTION 
Chemistry. All starting materials and reagents were obtained from commercial 
suppliers and were used without further purification. Air and moisture sensitive 
reactions were performed under an argon atmosphere. Flash column 
chromatography was performed using silica gel 60 (2302400 mesh, Merck) with 
the indicated solvents. Thin2layer chromatography was performed using 0.25 mm 
silica gel plates (Merck). 1H and 13C NMR spectra were recorded on a Bruker 600 
MHz spectrometer as solutions in deuteriochloroform (CDCl3) or methanol2d4. 
1H 
NMR data were reported in the order of chemical shift, multiplicity (s, singlet; d, 
doublet; t, triplet; m, multiplet and/or multiple resonances), number of protons, and 
coupling constant (J) in hertz (Hz). High2resolution mass spectra (HRMS) were 
recorded on a JEOL JMS2700 (FAB and EI) and an Agilent 6530 Q2TOF 
LC/MS/MS system (ESI). All assayed compounds had purity ≥95% as determined 
by HPLC (Supplementary Table 2). 
7-Hydroxy-5,6-dimethoxychroman-4-one (6a). To a solution of 12(42
(benzyloxy)262hydroxy22,32dimethoxyphenyl)ethanone (100 mg, 0.33 mmol) in 
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toluene (2.0 mL) was added N,N2dimethylformamide dimethyl acetal (0.052 mL, 
0.39 mmol). After stirring for 18 h at 80 °C, the mixture was cooled to 0 °C and c2
HCl (0.2 mL) was added. After stirring for 1 h at 50 °C, The reaction mixture was 
diluted with ethyl acetate and the organic phase was washed with water and brine, 
and dried over anhydrous MgSO4. The solvent was removed under reduced 
pressure and purified by flash column chromatograph on silica gel (ethyl acetate : 
n2hexane = 1 : 2) to afford 72(benzyloxy)25,62dimethoxy24H2chromen242one (101 
mg, 97%). 1H2NMR (CDCl3, 600 MHz) δ 7.63 (d, 1H, J = 6.0 Hz), 7.4627.40 (m, 
4H), 7.37 (t, 1H, J = 6.6 Hz), 6.7 (s, 1H), 6.1 (d, 1H, J = 6.0 Hz), 5.20 (s, 2H), 3.97 
(s, 3H) , 3.92 (s, 3H); 13C2NMR (150 MHz, CDCl3) δ 176.2, 156.8, 154.6, 152.9, 
140.7, 135.5, 128.8, 128.4, 127.2, 114.2, 113.8, 97.6, 70.9, 62.1, 61.5, 30.9. An 
anhydrous MeOH solution of the above 42chromenone (47 mg, 0.15 mmol) and 
10% Pd/C (16 mg) was placed under an atmosphere of hydrogen. After stirring for 
1 h, the reaction mixture was diluted with ethyl acetate, filtered through a Celite 
pad and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the 
chroman242one (6a) (33 mg, 99%). 1H2NMR (CDCl3, 600 MHz) δ 6.31 (s, 2H), 
4.43 (t, 2H, J = 6.6 Hz), 3.90 (s, 3H), 3.90 (s, 3H), 2.72 (d, 2H, J = 6.6 Hz). 13C2
NMR (150 MHz, CDCl3) δ 189.3, 160.1, 155.5, 153.3, 135.1, 109.6, 98.9, 66.6, 
Page 27 of 64
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 28
61.5, 61.43, 38.7; HRMS (ESI): mass calcd for C11H12O5 [M + H
+], 224.0685; 
found, 224.0677. 
5,6,7-Trimethoxychroman-4-one (6b). Chromen242one formation of 12(62
hydroxy22,3,42trimethoxyphenyl)ethan212one with N,N2dimethylformamide 
dimethyl acetal followed by the catalytic hydrogenation, performed according to 
the procedure described above, gave the chroman242one (6b) in 94% yield. 1H2
NMR (CDCl3, 600 MHz) δ 6.22 (s, 1H), 4.42 (t, 2H, J = 6.6 Hz), 3.88 (s, 3H), 3.84 
(s, 3H), 3.77 (s, 3H), 2.69 (t, 2H, J = 6.6 Hz); 13C2NMR (150 MHz, CDCl3) δ 
189.1, 160.0, 159.3, 154.3, 137.3, 109.6, 96.0, 66.8, 61.5, 61.3, 56.0, 38.7. 
5,7-Dimethoxychroman-4-one (6c). Chromen242one formation of 12(22hydroxy2
4,62dimethoxyphenyl)ethan212one with N,N2dimethylformamide dimethyl acetal 
followed by the catalytic hydrogenation, performed according to the procedure 
described above, gave the chroman242one (6c) in 95% yield. 1H2NMR (CDCl3, 600 
MHz) δ 6.06 (s, 2H), 4.45 (t, 2H, J = 6.6 Hz), 3.87 (s, 3H), 3.82 (s, 3H), 2.73 (d, 
2H, J = 6.6 Hz); 13C2NMR (150 MHz, CDCl3) δ 189.1, 165.7, 165.2, 162.3, 106.4, 
93.3, 92.9, 66.8, 56.1, 55.5, 38.8. 
(E)-7-Hydroxy-3-(3′-hydroxy-4′-methoxybenzylidene)-5,6-
dimethoxychroman-4-one (7a). To a solution of the chroman242one (6a) (32 mg, 
0.14 mmol) in benzene (3 mL) was added isovanillin (26 mg, 1.7 mmol) and p2
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toluenesulfonic acid (3 mg) at 0 °C. The reaction mixture was refluxed for 10 h. 
After cooling to room temperature, the reaction mixture was concentrated under 
reduced pressure to afford the title product. The residue was used in subsequent 
reactions without further purification. HRMS (ESI): mass calcd for C19H18O7 [M + 
H+], 358.1053; found, 358.1073. 
(E)-3-(3′-Hydroxy-4′-methoxybenzylidene)-5,6,7-trimethoxychroman-4-one 
(7b). To a solution of the chroman242one (6b) (238 mg, 1.0 mmol) in benzene (25 
mL) was added isovanillin (170 mg, 1.1 mmol) and p2toluenesulfonic acid (20 mg, 
0.1 mmol) at 0 °C. The reaction mixture was refluxed for 12 h. After cooling to 
room temperature, the reaction mixture was concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (ethyl 
acetate / n2hexane = 1 : 1) to afford the 32benzylidene2chroman242one (7b) (215 
mg, 58%). 1H2NMR (600 MHz, CDCl3) δ 7.74 (s, 1H), 6.9126.84 (m, 3H), 6.26 (s, 
1H), 5.67 (s, 1H), 5.24 (d, 2H, J = 1.8 Hz); 3.98 (s, 3H), 3.94 (s, 3H), 3.88 (s, 3H), 
3.83 (s, 3H); 13C2NMR (150 MHz, CDCl3) δ 179.5, 159.3, 159.1, 154.7, 147.5, 
145.5, 137.8, 136.2, 130.1, 128.1, 123.2, 115.7, 110.5, 96.1, 67.6, 61.6, 61.3, 60.3, 
60.3, 56.0, 55.9; HRMS (EI): mass calcd for C20H20O7 [M
+], 372.1209; found, 
372.1208. 
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(E)-3-(3′-Hydroxy-4′-methoxybenzylidene)-5,7-dimethoxychroman-4-one 
(7c). To a solution of the chroman242one (6c) (71 mg, 0.34 mmol) in benzene (2 
mL) was added isovanillin (62 mg, 0.41 mmol) and p2toluenesulfonic acid (7 mg, 
0.03 mmol) at 0 °C. The reaction mixture was refluxed for 12 h. After cooling to 
room temperature, the reaction mixture was concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (ethyl 
acetate : n2hexane = 1 : 1) to afford the 32benzylidene2chroman242one (7c) (72 mg, 
62%). 1H2NMR (600 MHz, CDCl3) δ 7.72 (s, 1H), 6.8926.87 (m, 2H), 6.83 (d, 1H, 
J = 8.4Hz), 6.11 (s, 1H), 6.06 (s, 1H), 5.23 (s, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 3.82 
(s, 3H); 13C2NMR (150 MHz, CDCl3) δ 179.5, 165.6, 164.6, 162.7, 147.4, 145.5, 
135.7, 130.5, 128.3, 123.0, 115.8, 110.5, 107.3, 9305, 93.5, 67.6, 56.1, 56.0, 55.5; 
HRMS (EI): mass calcd for C19H18O6 [M
+], 342.1103; found, 342.1101. 
7-Hydroxy-3-(3′-hydroxy-4′-methoxybenzyl)-5,6-dimethoxychroman-4-one 
(8). A solution of the 32benzylidene2chroman242one (7a) (35 mg, 0.07 mmol) and 
10% Pd/C (10 mg) in MeOH was placed under an atmosphere of hydrogen. After 
stirring for 1 h, the reaction mixture was diluted with ethyl acetate, filtered through 
a Celite pad and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 1) to 
afford the 32benzyl2chroman242one (8) (22 mg, 87%). 1H2NMR (600 MHz, 
CD3OD) δ 6.82 (d, 1H, J = 14.4 Hz), 6.67 (d, 1H, J = 1.8 Hz), 6.63 (dd, 1H, J = 8.4 
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and 2.4 Hz), 6.16 (s, 1H), 4.21 (dd, 1H, J = 11.4 and 4.2 Hz), 4.04 (dd, 1H, J = 
11.4 and 7.2 Hz), 3.82 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 3.00 (dd, 1H, J = 13.2 
and 4.2 Hz), 2.66 (m, 1H), 2.58 (dd, 1H, J = 13.8 and 10.8Hz); 13C2NMR (150 
MHz, CD3OD) δ 192.4, 160.0, 158.5, 154.4, 146.3, 146.2, 136.4, 131.2, 119.9, 
115.6, 111.5, 107.3, 99.1, 68.6, 60.4, 60.1, 55.0, 48.2, 32.0; HRMS (ESI): mass 
calcd for C19H20O7 [M + H
+], 361.1287; found, 361.1270. Compound 8 was 
reported. See ref 7. 
3-(3′-Hydroxy-4′-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (10). An 
anhydrous MeOH solution of the 32benzylidene2chroman242one (7b) (415 mg, 1.2 
mmol) and 5% Pd/C (59 mg) was placed under an atmosphere of hydrogen. After 
stirring for 1 h, the reaction mixture was diluted with ethyl acetate, filtered through 
a Celite pad and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 1) to 
afford the 32benzyl2chroman242one (10) (327 mg, 78%). 1H2NMR (400 MHz, 
CDCl3) δ 7.24 (s, 1H), 6.83 (d, 1H, J = 7.8 Hz); 6.71 (d, 2H, J = 1.9 Hz); 6.23 (s, 
1H), 5.53 (s, 1H), 4.23 (m, 1H), 4.10 (m, 1H), 3.91 (s, 3H), 3.85 (d, 6H, J = 1.9 
Hz); 3.79 (s, 3H), 3.16 (m, 1H), 2.70 (m, 1H), 2.63 (m, 1H); 13C2NMR (100 MHz, 
CDCl3) δ 191.3, 159.6, 159.2, 154.4, 146.5, 144.2, 137.4, 130.2, 121.8, 114.3, 
111.4, 108.6, 95.9, 69.0, 61.5, 61.2, 56.0, 55.9, 48.5, 32.5. HRMS (ESI): mass 
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calcd for C20H22O7 [M + H
+], 375.1444; found, 375.1432. Compound 10 was 
reported. See ref 5. 
5-Hydroxy-3-(3′-hydroxy-4′-methoxybenzyl)-6,7-dimethoxychroman-4-one 
(9). To a CHCl3 solution (2 mL) of the 32benzyl2chroman242one (10) (60 mg, 0.16 
mmol) was added TMSI (50 SL, 0.4 mmol) at 0 °C and the reaction mixture was 
stirred at room temperature for 1 h. The reaction mixture was concentrated under 
reduced pressure. The residue was purified by flash column chromatography on 
silica gel (ethyl acetate : n2hexane = 1 : 2) to afforded the demethylated 32benzyl2
chroman242one (9) (23 mg, 42%). 1H2NMR (400 MHz, CDCl3) δ 11.96 (s, 1H), 
6.86 (d, 1H, J = 7.8 Hz), 6.7226.70 (m, 2H), 6.02 (s, 1H), 5.60 (s, 1H), 4.30 (dd, 
1H, J = 11 and 4.3 Hz), 4.14 (dd, 1H, J = 6.8 and 11 Hz), 3.87 (s, 6H), 3.82 (s, 
3H), 3.17 (dd, 1H, J = 13 and 3.9 Hz), 2.8322.77 (m, 1H), 2.72 (dd, 1H, J = 13 and 
10 Hz); 13C2NMR (100 MHz, CDCl3) δ 198.4, 160.7. 158.7. 155.2. 146.6. 144.1. 
130.4. 129.5. 121.8. 114.4. 111.3. 102.6. 91.2. 69.1. 60.8. 56.1. 55.8. 46.8. 32.4; 
HRMS (ESI): mass calcd for C20H22O7 [M + H
+], 375.1439; found, 375.1459. 
Compound 9 was reported. See ref 7. 
3-(3′-Hydroxy-4′-methoxybenzyl)-5,7-dimethoxychroman-4-one (11). An 
anhydrous MeOH solution of the 32benzylidene2chroman242one (7c) (12 mg, 0.04 
mmol) and 10% Pd/C (4 mg) was placed under an atmosphere of hydrogen. After 
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stirring for 1 h, the reaction mixture was diluted with ethyl acetate, filtered through 
a Celite pad and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 1 ) to 
afford the 32benzyl2chroman242one (11) (10 mg, 73%). 1H2NMR (600 MHz, 
CDCl3) δ 6.8126.77 (m, 2H), 6.71 (d, 1H, J = 8.4 Hz), 6.06 (d, 1H, J = 8.4 Hz), 
5.58 (s, 1H), 4.27 (dd, 1H, J = 11.4 and 4.2 Hz), 4.10 (dd, 1H, J = 10.8 and 7.2 
Hz), 3.88 (s, 3H), 3.87 (s, 3H), 3.82 (s, 3H), 3.19 (dd, 1H, J = 13.8 and 4.2 Hz), 
2.7522.72 (m, 1H), 2.58 (t, 1H, J =12.6 Hz); 13C2NMR (150 MHz, CDCl3)  δ 191.3, 
165.7, 164.9, 162.5, 145.6, 145.2, 131.9, 120.6, 115.2, 110.7, 105.4, 93.1, 92.9, 
68.9, 56.1, 56.0, 55.5, 48.4, 32.2;  HRMS (EI): mass calcd for C19H20O6 [M
+], 
344.1260; found, 344.1267. 
(E)-3-(3′-(Benzyloxy)-4′-methoxybenzylidene)-5,6,7-trimethoxychroman-4-
one (7d). To an acetone (5 mL) solution of the 32benzylidene2chroman242one (7b) 
(124 mg, 0.33 mmol) benzyl bromide (70 mg, 0.4 mmol) and K2CO3 (144 mg, 0.80 
mmol) were added. After stirring for 3 h at room temperature, the reaction mixture 
was diluted with ethyl acetate and the organic phase was washed with water and 
brine, dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 
: 1) to afford the benzylated 32benzylidene2chroman242one (7d) (120 mg, 79%). 
1H2NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.4227.24 (m, 5H), 6.93 (d, 1H, J = 8.3 
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Hz); 6.87 (dd, 1H, J = 8.3 and 2.0 Hz); 6.75 (d, 1H, J = 2.0 Hz); 6.22 (s, 1H), 5.17 
(s, 2H), 5.03 (d, 2H, J = 1.5 Hz); 3.95 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H), 3.81 (s, 
3H); 13C2NMR (100 MHz, CDCl3) δ 179.4, 159.3, 159.1, 154.7, 150.8, 147.8, 
137.8, 136.7, 136.2, 129.9, 128.6, 128.0, 127.3, 127.1, 124.0, 115.9, 111.5, 110.5, 
96.1, 71.1, 67.4, 61.6, 61.3, 56.1, 56.0; HRMS (EI): mass calcd for C27H26O7 [M
+], 
462.1679; found, 462.1679. 
(E)-3-(3′-(Allyloxy)-4′-methoxybenzylidene)-5,6,7-trimethoxychroman-4-one 
(7e). To an acetone (2 mL) solution of the 32benzylidene2chroman242one (7b) (9.9 
mg, 0.02 mmol) allylbromide (2.5 SL, 0.02 mmol) and K2CO3 (18 mg, 0.10 mmol) 
were added. After stirring for 3 h at room temperature, the reaction mixture was 
diluted with ethyl acetate and the organic phase was washed with water and brine, 
dried over anhydrous MgSO4 and concentrated under reduced pressure. The residue 
was purified by flash column chromatography (ethyl acetate : n2hexane = 1 : 1) to 
afford the allylated 32benzylidene2chroman242one (7e) (6.8 mg, 83%). 1H2NMR 
(600 MHz, CDCl3) δ 7.75 (s, 1H), 6.93 (d, 1H, J = 8.4 Hz), 6.88 (dd, 1H, J = 8.4 
and 1.8 Hz), 6.83 (d, 1H, J = 1.8 Hz), 6.25 (s, 1H), 6.11 2 6.04 (m, 1H), 5.43 2 5.40 
(m, 1H), 5.33 – 5.31 (m, 1H), 5.23 (d, 1H, J = 1.8 Hz), 4.64 (m, 2H), 3.97 (s, 3H), 
3.91(s, 3H), 3.88 (s, 3H), 3.83 (s, 3H); 13C2NMR (150 MHz, CDCl3) δ 179.51, 
159.32, 159.19, 154.78, 150.57, 147.82, 137.88, 136.36, 133.05, 130.01, 127.41, 
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123.76, 118.32, 115.26, 111.36, 110.64, 96.15, 69.99, 67.70, 61.66, 61.35, 56.13, 
56.01; HRMS (EI): mass calcd for C23H24O7 [M
+], 412.1522; found, 412.1519. 
(E)-5,6,7-Trimethoxy-3-(4′-methoxy-3′-nitrobenzylidene)chroman-4-one (7f). 
To a benzene solution (2 mL) of the chroman242one (6b) (17 mg, 0.071 mmol) 
were added 42methoxy232nitrobenzaldehyde (13 mg, 0.071 mmol) and p2
toluenesulfonic acid (2 mg, 0.1 mmol) at 0 °C. After refluxing for 12 h with a 
Dean2Stark apparatus, the reaction mixture was cooled and quenched with 
saturated NaHCO3. The reaction mixture was diluted with ethyl acetate (5 mL x 3) 
and washed with water and the combined organic phases were dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 
: 1) to afford the 32benzylidene2chroman242one (7f) (17 mg, 60%). 1H2NMR (600 
MHz, CDCl3) δ 7.76 (d, 1H, J = 2.4 Hz), 7.72 (s, 1H) 7.51 (dd, 1H, J = 9.0 and 2.4 
Hz), 7.17 (d, 1H, J = 8.4 Hz), 6.26 (s,1H), 5.20 (d, 2H, J = 1.8 Hz), 4.02 (s, 3H), 
3.98 (s, 3H), 3.89 (s, 3H), 3.83 (s, 3H); 13C2NMR (150 MHz, CDCl3) δ 178.8, 
159.5, 159.4, 154.8, 153.3, 139.5, 138.0, 135.7, 133.0, 132.4, 127.1, 126.5, 113.8, 
110.3, 96.2, 67.1, 61.6, 61.3, 56.7, 56.2; HRMS (EI): mass calcd for C20H19NO8 
[M+], 401.1111; found, 401.1113. 
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Methyl (E)-2-methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-ylidene) 
methyl)benzoate (7g). To a benzene solution (2 mL) of the chroman242one (6b) 
(103 mg, 0.43 mmol) were added methyl 52formylsalicylate (78 mg, 0.43 mmol) 
and p2toluenesulfonic acid (17 mg, 0.04 mmol) at 0 °C. After refluxing for 12 h 
with a Dean2Stark apparatus, the reaction mixture was cooled and quenched with 
saturated NaHCO3. The reaction mixture was diluted with ethyl acetate (5 mL x 3) 
and washed with water and the combined organic phases were dried over MgSO4, 
and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford 
methyl (E)222hydroxy252((5,6,72trimethoxy242oxochroman232ylidene)methyl) 
benzoate (115 mg, 66%). 1H2NMR (600 MHz, CDCl3) δ 10.87 (s, 1H), 7.66 (s, 
1H), 7.61 (s, 1H), 7.30 (d, 1H, J = 8.4 Hz), 6.93 (dd, 1H, J = 8.4 and 1.8 Hz), 6.15 
(s, 1H), 5.11 (s, 2H), 3.88 (s, 6H), 3.78 (s, 3H), 3.74 (s, 3H); 13C2NMR (150 MHz, 
CDCl3) δ 179.1, 169.9, 162.1, 159.2, 159.2, 154.7, 137.8, 137.0, 134.8, 131.7, 
130.6, 125.9, 118.1, 112.4, 110.4, 96.1, 67.3, 61.5, 61.2, 56.1, 52.6. To an acetone 
solution (3 mL) of methyl (E)222hydroxy252((5,6,72trimethoxy242oxochroman232
ylidene)methyl)benzoate (100 mg, 0.24 mmol) were added dimethyl sulfate (0.23 
mL, 2.4 mmol) and K2CO3 (138 mg, 0.72 mmol). After refluxing for 4h, the 
reaction mixture was diluted with ethyl acetate (10 mL x 3) and washed with water 
and the combined organic phases were dried over MgSO4, and concentrated under 
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reduced pressure. The residue was purified by flash column chromatography on 
silica gel (ethyl acetate : n2hexane = 1 : 1) to afford the 32benzylidene2chroman242
one (7g) (100 mg, 97%). 1H2NMR (600 MHz, CDCl3) δ 7.73 (s, 1H), 7.71 (d, 1H, J 
= 2.4 Hz), 7.41 (dd, 1H, J = 9 and 2.4 Hz), 7.03 (d, 1H, J = 8.4 Hz), 6.23 (s, 1H), 
5.20 (d, 2H, J = 1.2 Hz), 3.96 (s, 3H), 3.93 (s, 3H), 3.89 (s, 3H), 3.86 (s, 3H), 3.81 
(s, 3H); 13C2NMR (150 MHz, CDCl3) δ 179.2, 166.0, 159.6, 159.3, 159.3, 154.8, 
137.9, 135.3, 134.8, 133.2, 130.9, 126.7, 120.2, 112.2, 110.5, 96.1, 67.4, 61.6, 
61.3, 56.2, 56.1, 52.3; HRMS (EI): mass calcd for C22H22O8 [M
+], 414.1315; 
found, 414.1317. 
(E)-3-(3′-Fluoro-4′-methoxybenzylidene)-5,6,7-trimethoxychroman-4-one 
(7h). To a benzene solution (5 mL) of the chroman242one (6b) (101 mg, 0.42 
mmol) were added 32fluoro242hydroxybenzaldhyde (59 mg, 0.42 mmol) and p2
toluenesulfonic acid (17 mg, 0.08 mmol) at 0 °C. After refluxing for 12 h with a 
Dean2Stark apparatus, the reaction mixture was cooled and quenched with 
saturated NaHCO3. The reaction mixture was diluted with ethyl acetate (30 mL x 
3) and washed with water and the combined organic phases were dried over 
MgSO4, and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 1) to 
afford the 32benzylidene2chroman242one (7h) (62 mg, 40%). 1H2NMR (600 MHz, 
CDCl3) δ 7.67 (s, 1H), 7.0126.95 (m, 3H), 6.22 (s,1H), 5.18 (s, 2H), 3.94 (s, 3H), 
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3.90 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H); 13C2NMR (150 MHz, CDCl3) δ 179.2, 
159.3, 154.7, 152.8, 151.1, 148.6, 148.5, 137.9, 134.8, 130.8, 126.8, 117.4, 117.3, 
113.2, 110.5, 96.1, 67.4, 61.6, 61.3, 56.2; HRMS (EI): mass calcd for C20H19FO6 
[M+], 374.1166; found, 374.1166. 
(E)-3-(4′-hydroxy-3′-methoxybenzylidene)-5,6,7-trimethoxychroman-4-one 
(7i) and (E)-3-(4′-(benzyloxy)-3′-methoxybenzylidene)-5,6,7-
trimethoxychroman-4-one (7j). To a benzene solution (25 mL) of 5,6,72
trimethoxychroman242one (6b) (238 mg, 1.0 mmol) were added 42benzyloxy232
methoxybenzaldehyde (265 mg, 1.1 mmol) and p2toluenesulfonic acid (20 mg, 0.1 
mmol) at 0 °C. After refluxing for 12 h with a Dean2Stark apparatus, the reaction 
mixture was cooled and quenched with saturated NaHCO3. The reaction mixture 
was diluted with ethyl acetate (15 mL x 3) and washed with water and the 
combined organic phases were dried over anhydrous MgSO4, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography 
on silica gel (ethyl acetate : n2hexane = 1 : 1) to afford the 32benzylidene2chroman2
42ones (7j) (48 mg, 11%) and (7i) (62 mg, 17%). For 7i, 1H2NMR (600 MHz, 
CDCl3) δ 7.75 (s, 1H), 6.96 (s, 1H), 6.96 (d, 1H, J = 8.4 Hz), 6.82 (s, 1H), 6.79 (d, 
1H, J = 8.4 Hz), 5.24 (s, 2H), 3.97 (s, 3H), 3.90 (s, 3H), 3.87 (s, 3H), 3.83 (s, 3H); 
13C2NMR (150 MHz, CDCl3) δ 179.5, 159.3, 159.1, 154.7, 147.0, 146.5, 137.8, 
136.5, 129.8, 127.0, 123.7, 114.6, 112.7, 110.6, 96.1, 67.6, 61.6, 61.3, 56.1, 55.9; ; 
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HRMS (EI): mass calcd for C20H22O7 [M
+], 372.1209; found, 372.1210. For 7j, 1H2
NMR (600 MHz, CDCl3) δ 7.75 (s, 1H), 7.44–7.30 (m, 5H), 6.92 (d, 1H, J = 7.8 
Hz), 6.85 (s, 1H), 7.78 (d, 1H, J = 7.8 Hz), 6.25 (s, 1H), 5.23 (s, 2H), 5.20 (s, 2H), 
3.97 (s, 3H), 3.90 (s, 3H), 3.87 (s, 3H), 3.83 (s, 3H); 13C2NMR (150 MHz, CDCl3) 
δ 179.4, 159.3, 159.1, 154.7, 149.4, 149.2, 137.8, 136.5, 136.3, 130.1, 128.6, 
128.0, 127.9, 127.2, 123.1, 113.6, 113.3, 110.6, 96.1, 70.8, 67.6, 61.6, 61.3, 56.1, 
56.1; HRMS (EI): mass calcd for C27H26O7 [M
+], 462.1679; found, 462.1674.  
(E)-3-(3′,4′-Dihydroxybenzylidene)-5,6,7-trimethoxychroman-4-one (7k). To 
a benzene solution (3 mL) of the chroman242one (6b) (83 mg, 0.34 mmol) were 
added 3,42dihydroxybenzaldehyde (47 mg, 0.34 mmol) and p2toluenesulfonic acid 
(14 mg, 0.07 mmol) at 0 °C. After refluxing for 12 h with a Dean2Stark apparatus, 
the reaction mixture was cooled and quenched with saturated NaHCO3. The 
reaction mixture was diluted with ethyl acetate (10 mL x 3) and washed with water 
and the combined organic phases were dried over MgSO4, and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on 
silica gel (ethyl acetate : n2hexane = 1 : 1) to afford the 32benzylidene2chroman242
one (7k) (13 mg, 10%).1H2NMR (600 MHz, DMSO2d6) δ 7.52 (s, 1H), 6.8526.84 
(m, 2H), 6.78 (dd, 1H, J = 8.4 and 1.8 Hz), 6.49 (s, 1H), 5.27 (s,2H), 3.86 (s, 3H), 
3.81 (s, 3H), 3.69 (s, 3H); 13C2NMR (150 MHz, DMSO2d6) δ 178.8, 159.2, 159.2, 
154.4, 147.9, 154.7, 137.6, 136.3, 129.1, 125.8, 123.4, 117.9, 116.2, 110.5, 97.1, 
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67.8, 61.7, 61.2, 56.7; HRMS (EI): mass calcd for C19H18O7 [M
+], 358.1053; 
found, 358.1057. 
(E)-3-(3′,4′-Bis(benzyloxy)benzylidene)-5,6,7-trimethoxychroman-4-one (7l). 
To a benzene solution (5 mL) of the chroman242one (6b) (108 mg, 0.45 mmol) 
were added 3,42dibenzyloxybenzaldhyde (102 mg, 0.45 mmol) and p2
toluenesulfonic acid (9 mg, 0.04 mmol) at 0 °C. After refluxing for 12 h with a 
Dean2Stark apparatus, the reaction mixture was cooled and quenched with 
saturated NaHCO3. The reaction mixture was diluted with ethyl acetate (10 mL x 
3) and washed with water and the combined organic phases were dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 
: 2) to afford the 32benzylidene2chroman242one (7l) (110 mg, 45%). 1H2NMR (600 
MHz, CDCl3) δ 7.67 (s, 1H), 7.44 (t, 4H, J = 7.8 Hz), 7.37 (t, 4H, J= 7.8 Hz), 7.32 
(t, 2H, J = 7.2 Hz), 6.94 (d, 1H, J = 8.4 Hz), 6.80 (m, 2H), 6.22 (s, 1H), 5.20 (s, 
2H), 5.18 (s, 2H), 5.04 (d, 2H, J = 1.2 Hz), 3.95 (s, 3H), 3.86 (s, 3H), 3.81 (s, 3H); 
13C2NMR (150 MHz, CDCl3) δ 179.4, 159.3, 159.1, 154.7, 150.0, 148.4, 137.8, 
136.8, 136.7, 136.1, 128.6, 128.6, 128.0, 127.2, 124.1, 116.9, 114.2, 110.6, 96.1, 
71.4, 71.0, 67.5, 61.6, 61.3, 56.1; HRMS (EI): mass calcd for C33H30O7 [M
+], 
538.1992; found, 538.1992. 
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3-(3′-Amino-4′-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (12b). An 
anhydrous MeOH solution of 7f (12 mg, 0.05 mmol) and 10% Pd/C (4 mg) was 
placed under an atmosphere of hydrogen. After stirring for 1 h, the reaction 
mixture was diluted with Ethyl acetate, filtered through a Celite pad and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate : n-hexane = 1 : 1 ) to afford the 32
benzyl2chroman242one (12b) (13 mg, 73%). 1H2NMR (600 MHz, CDCl3) δ 6.70 (d, 
1H, J = 8.4 Hz), 6.58 (d, 1H, J = 1.8 Hz), 6.56 (dd, 1H, J = 8.4 and 2.4 Hz), 4.26 
(dd, 1H, J = 10.8 and 4.2 Hz), 4.11 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.81 (s, 
3H), 3.79 (s, 3H), 3.12 (dd, 1H, J = 14.4 and 4.2 Hz), 2.71 (m, 1H), 2.54 (dd, 1H, J 
= 13.8 and 10.8 Hz); 13C2NMR (150 MHz, CDCl3) δ 191.7, 166.4, 159.8, 159.2, 
136.1, 133.5, 131.2, 125.7, 118.9, 115.6, 110.4, 108.9, 95.9, 69.1, 61.6, 61.3, 56.0, 
55.5, 48.4, 32.1; HRMS (EI): mass calcd for C20H23NO6 [M
+], 373.1525; found, 
373.1519. 
Methyl 2-methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl) 
benzoate (12c). To an anhydrous MeOH (3 mL) solution of 7g (102 mg, 0.24 
mmol) and 10% Pd/C (26 mg) was placed under an atmosphere of hydrogen. After 
stirring for 1 h, the reaction mixture was diluted with ethyl acetate, filtered through 
a Celite pad and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2 ) to 
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afford the 32benzyl2chroman242one (12c) (72 mg, 74%). 1H2NMR (600 MHz, 
CDCl3) δ7.58 (d, 1H, J = 2.4 Hz), 7.29 (dd, 1H, J =8.4 and 2.4 Hz), 6.88 (d, 1H, J 
= 9Hz), 6.19 (s, 1H), 4.23 (dd, 1H, J =11.4 and 4.2 Hz), 4.03 (dd, 1H, J = 9 and 5.4 
Hz), 3.86 (s, 3H), 3.82 (s, 9H), 3.74 (s, 3H), 3.15 (dd, 1H, J = 13.8 and 4.2 Hz), 
2.72 (m, 1H), 2.63 (dd, 1H, J = 14.4 and 10.8 Hz); 13C2NMR (150 MHz, CDCl3) δ 
190.9, 166.5, 159.6, 159.3, 157.8, 154.4, 137.5, 134.1, 132.0, 130.1, 120.0, 112.3, 
108.6, 95.9, 69.0, 61.5, 61.2, 60.3, 56.0, 52.0, 58.1, 20.9; HRMS (EI): mass calcd 
for C22H24O8 [M
+], 416.1471; found, 416.1470. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)benzoic acid 
(12d). The methyl ester 12c (29 mg, 0.07 mmol) was suspended in 0.4 mL of THF. 
In a separate flask, 2.5 mg of lithium hydroxide was dissolved in 0.4 mL of 
deionized water. Both mixtures were chilled to 4 °C and combined to form a turbid 
white mixture. After 1 h of stirring, the mixture had become homogeneous. After 
24 h, 0.5 mL of 3 M HCl was added, and the mixture was allowed to warm to room 
temperature. The reaction mixture was diluted with ethyl acetate (3 mL x 3) and 
washed with water and the combined organic phases were dried over MgSO4, and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate : n2hexane = 1 : 1) to afford the 32
benzyl2chroman242one (12d) (16 mg, 56%).  1H2NMR (600 MHz, CD3OD) δ 7.31 
(d, 1H J = 1.8 Hz), 7.16 (dd, 1H, J = 8.4 and 2.4 Hz), 6.93 (d, 1H, J = 8.4 Hz), 6.39 
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(s, 1H), 4.30 (dd, 1H, J = 11.4 and 4.2 Hz), 4.13 (dd, 1H, J = 11.4 and 7.8 Hz), 
3.87 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.74 (s, 3H), 3.11 (dd, 1H, J = 13.8 and 4.2 
Hz), 2.77 (m, 1H), 2.66 (dd, 1H, J = 14.4 and 10.8 Hz); 13C2NMR (150 MHz, 
CD3OD) δ 192.3, 160.2, 159.8, 155.2, 153.9, 137.1, 129.7, 129.7, 129.0, 111.3, 
108.0, 96.0, 68.8, 60.7, 60.6, 60.2, 59.9, 55.3, 54.6, 31.5, 22.5; HRMS (EI): mass 
calcd for C21H22O8 [M
+], 402.1315; found, 402.1317. 
3-(3′-(Benzyloxy)-4′-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (12e). 
To an acetone (5 mL) solution of 10 (33 mg, 0.08 mmol), benzyl bromide (16 SL, 
0.12 mmol) and K2CO3 (37 mg, 0.25 mmol) were added. After stirring for 3 h at 
room temperature, the reaction mixture was diluted with ethyl acetate and the 
organic phase was washed with water and brine, dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the 32
benzyl2chroman242one (12e) (34 mg, 84%). 1H2NMR (600 MHz, CDCl3) δ 7.58 (d, 
1H, J = 2.4 Hz), 7.29 (dd, 1H, J = 8.4 and 2.4 Hz), 6.88 (d, 1H, J = 9 Hz), 6.19 (s, 
1H), 4.23 (dd, 1H, J =11.4 and 4.2 Hz), 4.03 (dd, 1H, J = 9 and 5.4 Hz), 3.86 (s, 
3H), 3.82 (s, 9H), 3.74 (s, 3H), 3.15 (dd, 1H, J = 13.8 and 4.2 Hz), 2.72 (m, 1H), 
2.63 (dd, 1H, J = 14.4 and 10.8 Hz); 13C2NMR (150 MHz, CDCl3) δ 190.9, 166.5, 
159.6, 159.3, 157.8, 154.4, 137.5, 134.1, 132.0, 130.1, 120.0, 112.3, 108.6, 95.9, 
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69.0, 61.5, 61.2, 60.3, 56.0, 52.0, 58.1, 20.9; HRMS (EI): mass calcd for C27H28O7 
[M+], 464.1835; found, 464.1837. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl 
benzoate (12f). To an acetone (5 mL) solution of 10 (36 mg, 0.09 mmol), benzoyl 
chloride (17 SL, 0.11 mmol) and K2CO3 (41 mg, 0.29 mmol) were added. After 
stirring for 17 h at room temperature, the reaction mixture was diluted with ethyl 
acetate and the organic phase was washed with water and brine, dried over MgSO4 
and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the 
32benzyl2chroman242one (12f) (38 mg, 82%). 1H2NMR (600 MHz, CDCl3) δ 8.19 
(dd, 1H, J = 8.4 and 1.2 Hz), 7.62 (t, 1H, J = 7.2 Hz), 7.50 (t, 2H, J = 7.8 Hz), 7.10 
(dd, 1H, J = 8.4 and 1.8 Hz), 7.02 (d, 1H, J = 2.4 Hz), 6.94 (d, 1H, J = 8.4 Hz), 
6.23 (s, 1H), 4.29 (dd, 1H, J = 11.4 and 4.2 Hz), 4.13 (dd, 1H, J = 11.4 and 7.8 
Hz), 3.90 (s, 3H), 3.85 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.21 (dd, 1H, J = 13.8 
and 4.2 Hz), 2.7622.72 (m 1H), 2.67 (dd, 1H, J = 13.8 and 4.8 Hz); 13C2NMR (150 
MHz, CDCl3) δ 191.1, 164.7, 159.7, 159.3, 154.5, 150.0, 139.9, 137.5, 133.5, 
131.0, 130.3, 129.3, 128.5, 127.4, 123.6, 112.7, 108.7, 96.0, 69.0, 61.6, 61.3, 56.1, 
56.0, 48.3, 31.9 ; HRMS (EI): mass calcd for C27H26O8 [M
+], 478.1628; found, 
478.1628. 
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2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl 
cinnamate (12g). To an acetone (5 mL) solution of 10 (77 mg, 0.2 mmol), 
cinnamoyl chloride (41 mg, 0.24 mmol) and K2CO3 (86 mg, 0.6 mmol) were 
added. After stirring for 17 h at room temperature, the reaction mixture was diluted 
with ethyl acetate and the organic phase was washed with water and brine, dried 
over MgSO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (Ethyl acetate / n2hexane = 1 : 2) to 
afford the 32benzyl2chroman242one (12g) (80 mg, 77%). 1H2NMR (600 MHz, 
CDCl3) δ 7.86 (d, 1H, J = 16.2 Hz), 7.56 (d, 2H, J = 3.0 Hz), 7.40 (t, 3H, J = 2.4 
Hz), 7.08 (d, 1H, J = 8.4 Hz), 6.98 (d, 1H, J = 1.8 Hz), 6.93 (d, 1H, J = 8.4 Hz), 
6.65 (d, 1H, J = 15.6 Hz), 6.23 (s, 1H), 4.30 (dd, 1H, J = 11.4 and 4.2 Hz), 4.12 
(dd, 1H, J = 12 and 7.8 Hz), 3.91 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 
3.20 (dd, 1H, J = 13.8 and 4.2 Hz), 2.7522.71 (m,1H), 2.66 (dd, 1H, J = 14.4 and 
10.8 Hz); 13C2NMR (150 MHz, CDCl3) δ 191.1, 164.9, 159.7, 159.3, 154.5, 149.9, 
146.6, 139.7, 137.5, 134.2, 131.0, 130.6, 129.0, 128.3, 127.3, 123.6, 116.9, 112.6, 
108.7, 96.0, 69.0, 61.6, 61.3, 56.1, 56.0, 48.3, 31.8 ; HRMS (EI): mass calcd for 
C29H28O8 [M
+], 504.1784; found, 504.1779. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl 3-
phenylpropanoate (12h). An anhydrous MeOH solution of 12g (28 mg, 0.05 
mmol) and 10% Pd/C (6 mg) was placed under an atmosphere of hydrogen. After 
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stirring for 1 h, the reaction mixture was diluted with Ethyl acetate, filtered through 
a Celite pad and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (ethyl acetate : n-hexane = 1 : 1 ) to 
afford the 32benzyl2chroman242one (12h) (26 mg, 92 %). 1H2NMR (600 MHz, 
CDCl3) δ 7.3327.22 (m, 5H), 7.06 (d, 1H, J = 8.4 Hz), 6.90 (d, 1H, J = 7.8 Hz), 
6.84 (s, 1H), 6.25 (s, 1H), 4.28 (dd, 1H, J = 11.4 and 4.2 Hz), 4.10 (dd, 1H, J = 
10.8 and 4.2 Hz), 3.93 (s, 3H), 3.88 (s, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 3.19 (dd, 
1H, J = 14.4 and 4.2 Hz), 3.10 (t, 2H, J = 7.8 Hz), 2.92 (t, 2H, J = 7.8 Hz), 2.742
2.71 (m, 1H), 2.64 (dd, 1H, J = 13.8 and 10.8 Hz);  13C2NMR (150 MHz, CDCl3) δ 
191.1, 170.9, 159.7, 159.3, 154.5, 149.8, 140.3, 139.7, 137.5, 131.0, 128.5, 128.4, 
127.3, 126.3, 123.4, 112.5, 108.7, 96.0, 69.0, 61.6, 61.3, 56.1, 55.9, 48.2, 35.5, 
31.8, 30.9; HRMS (EI): mass calcd for C29H30O8 [M
+], 506.1941; found, 506.1944. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl 
diethylcarbamate (12i). To a toluene (1 mL) solution of 10 (16 mg, 0.04 mmol), 
diethyl carbamoyl chloride (6 μL, 0.05 mmol) and Et3N (17 μL, 0.12 mmol) were 
added. After refluxing for 17 h, the reaction mixture was diluted with ethyl acetate 
and the organic phase was washed with water and brine, dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate : n2hexane = 1 : 1) to afford the 32
benzyl2chroman242one (12i) (8 mg, 40%). 1H2NMR (600 MHz, CDCl3) δ 7.0 (d, 
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1H, J = 8.4 Hz), 6.95 (s, 1H), 6.86 (d, 1H, J = 8.4 Hz), 6.22 (s, 1H), 4.28 (dd, 1H, J 
= 11.4 and 4.2 Hz), 4.10 (dd, 1H, J = 11.4 and 7.8 Hz), 3.90 (s, 3H), 3.85 (s, 3H), 
3.79 (s, 6H), 3.43 (d, 2H, J = 6.6 Hz), 3.36 (d, 2H, J = 6.6 Hz), 3.18 (dd, 1H, J = 
13.8 and 3.6 Hz), 2.7422.70 (m, 1H), 2.62 (dd, 1H, J = 13.8 and 10.8 Hz); 13C2
NMR (150 MHz, CDCl3) δ 191.2, 159.7, 159.2, 154.4, 154.0, 150.4, 140.6, 137.4, 
130.8, 126.6, 124.0, 112.5, 108.7, 96.0, 69.0, 61.6, 61.3, 56.1, 56.0, 48.3, 42.2, 
42.0, 31.8, 14.0, 13.4; HRMS (EI): mass calcd for C25H31NO8 [M
+], 473.2050; 
found, 473.2040. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl (tert-
butoxycarbonyl)-L-phenylalaninate (14a). To a CH2Cl2 solution (6 mL) of 10 
(169 mg, 0.45 mmol) were added Boc2Phe2OH (155 mg, 0.54 mmol), EDCI (84 
mg, 0.54 mmol) and DMAP (11 mg, 0.09 mmol). After stirring for 17 h, the 
reaction mixture was diluted with CH2Cl2 and washed with water and brine, dried 
over anhydrous MgSO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 
: 2) to afford the acylated 32benzyl2chroman242one (14a) (247 mg, 87%). 1H2NMR 
(600 MHz, CDCl3) δ 7.34 (m, 2H), 7.29 (m, 3H), 7.08 (dd, 1H, J = 8.4 and 1.8 
Hz), 6.92 (d, 1H, J = 8.4 Hz), 6.83 (bs, 1H), 6.25 ( s, 1H) 4.88 (m, 1H), 4.29 (dd, 
1H, J = 14 and 4.2 Hz), 4.10 (m, 1H), 4.1324.07 (m, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 
3.81 (s, 3H), 3.80 (s, 3H), 3.35 (m, 1H), 3.23 (m, 1H), 3.19 (m,1H), 2.72 (m, 1H), 
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2.64 (m, 1H), 1.42 (s, 9H); 13C2NMR (150 MHz, CDCl3) δ 191.0, 170.2, 159.7, 
159.4, 154.4, 150.9, 137.5, 136.0, 131.0, 129.6, 128.5, 127.0, 122.6, 121.3, 113.1, 
112.6, 108.6, 96.0, 79.9, 69.0, 61.6, 61.3, 56.1, 55.8, 54.3, 48.2, 38.2, 32.7, 31.8, 
28.3; HRMS (EI): mass calcd for C34H39NO10 [M 
+], 621.2574; found, 621.2573. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl (2S)-
3-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (14b). To 
a CH2Cl2 solution (2 mL) of 10 (63 mg, 0.16 mmol) were added Boc2Tyr(Bzl)2OH 
(75 mg, 0.19 mmol), EDCI (40 mg, 0.24 mmol) and DMAP (4 mg, 0.03 mmol). 
After stirring for 17 h, the reaction mixture was diluted with CH2Cl2 and washed 
with water and brine, dried over MgSO4 and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (ethyl 
acetate : n2hexane = 1 : 2) to afford the acylated 32benzyl2chroman242one (14b) 
(115 mg, 94%). 1H2NMR (600 MHz, CDCl3) δ 7.39 (d, 2H, J = 7.2 Hz), 7.33 (t, 
3H, J = 7.2 Hz), 7.28 (t, 1H, J = 7.2 Hz), 7.19 (d, 2H, J = 8.4 Hz), 7.05 (dd, 1H, J 
= 8.4 and 1.8 Hz), 6.92 (m, 3H), 6.22 (d, 1H, J = 2.4 Hz), 5.01 (s, 2H), 4.80 (m, 
1H), 4.26 (dd, 1H, J = 11.4 and 4.2 Hz), 4.06 (dd, 1H, J = 7.8 and 3.6 Hz), 3.89 (s, 
3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.76 (s, 3H), 3.26 (dd, 1H, J = 14.4 and 6.0 Hz), 
3.16 (dd, 1H, J = 13.8 and 4.2 Hz), 2.72 (m, 1H), 2.62 (m, 1H), 1.40 (s, 9H); 13C2
NMR (150 MHz, CDCl3) δ 191.0, 170.1, 159.6, 159.3, 157.9, 155.0, 154.4, 149.6, 
139.2, 137.5, 136.9, 131.0, 130.6, 128.5, 128.2, 127.9, 127.6, 127.4, 123.4, 114.8, 
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112.6, 108.6, 96.0, 79.9, 70.0, 68.9, 61.6, 61.3, 56.0, 55.8, 54.4, 48.2, 37.3, 31.8, 
28.3; HRMS (ESI): mass calcd for C41H45NO11 [M + H
+], 727.2993; found, 
727.302. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl (2S)-
3-(4-(allyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (14c). To a 
CH2Cl2 solution (3 mL) of 10 (56 mg, 0.15 mmol) were added Boc2Tyr(All)2OH 
(58 mg, 0.18 mmol), EDCI (35 mg, 0.22 mmol) and DMAP (4 mg, 0.03 mmol). 
After stirring for 17 h, the reaction mixture was diluted with CH2Cl2 and washed 
with water and brine, dried over MgSO4 and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (Ethyl 
acetate / n2hexane = 1 : 2) to afford the acylated 32benzyl2chroman242one (14c) (85 
mg, 84%).  1H2NMR (600 MHz, CDCl3) δ 7.16 (d, 1H, J = 8.4 Hz), 7.04 (dd, 1H, J 
= 8.4 and 1.8 Hz), 6.88 (d, 1H, J = 8.4 Hz), 6.85 (d, 3H J = 12 Hz), 6.22 (d, 1H, J 
=2.4 Hz), 6.0325.96 (m, 1H), 5.37 (dd, 1H, J = 16.8 and 1.2 Hz), 5.24 (dd, 1H, J = 
10.8 and 1.2 Hz), 5.02 (d, 1H, J = 7.8 Hz), 4.79 (q, 1H, J = 6.0 Hz), 4.48 (dd, 2H, J 
= 5.4 and 1.2 Hz), 4.25 (dd, 1H, J = 11.4 and 4.2 Hz), 4.04 (m, 1H), 3.89 (s, 3H), 
3.83 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H), 3.24 (dd, 1H, J = 14.4 and 6.0 Hz), 3.15 
(dd, 1H, J = 13.8 and 7.2 Hz), 2.7122.66 (m, 1H), 2.61 (dd, 1H, J = 13.8 and 10.2 
Hz), 1.39 (s, 9H); 13C2NMR (150 MHz, CDCl3) δ 191.0, 170.1, 159.6, 159.3, 
157.7, 155.0, 154.4, 149.6, 139.2, 137.4, 133.2, 131.0, 130.5, 128.1, 127.5, 123.4, 
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117.5, 114.7, 112.6, 108.6, 96.0, 79.9, 68.9, 68.7, 61.5, 61.2, 56.0, 55.8, 54.4, 48.1, 
37.3, 31.8, 28.2; HRMS (ESI): mass calcd for C37H43NO11 [M + H
+], 677.2836; 
found, 677.2847. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl (tert-
butoxycarbonyl)-L-isoleucinate (14d). To a CH2Cl2 solution (3 mL) of 10 (22 
mg, 0.05 mmol) were added Boc2Ile2OH (15 mg, 0.06 mmol), DCC (13 mg, 0.6 
mmol) and DMAP (1 mg, 0.01 mmol). After stirring for 17 h, the reaction mixture 
was diluted with CH2Cl2 and washed with water and brine, dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the 
acylated 32benzyl2chroman242one (14d) (33 mg, 95%). 1H2NMR (600 MHz, 
CDCl3) δ 7.18 (d, 2H, J = 7.8 Hz), 7.09 (dd, 1H, J = 8.4 and 2.4 Hz), 6.95 (m, 4H), 
6.26 (s, 1H), 5.01 (m, 1H), 4.85 (dd, 1H, J = 8.4 and 6.0 Hz), 4.29 (dd, 1H, J = 
10.8 and 4.2 Hz), 4.10 (m, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.81 (s, 3H), 3.80 (s, 
3H), 3.48 (m, 1H), 3.32 (dd, 1H, J = 14.4 and 6.0 Hz), 3.20 (dd, 1H, J = 13.8 and 
4.2Hz), 2.75 (m, 1H), 2.64 (m, 1H), 1.42 (s, 9H), 1.32 (s, 9H); HRMS (FAB): mass 
calcd for C31H41NO10 [M+ H
+], 588.2730; found, 588.2807. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl (tert-
butoxycarbonyl)-L-leucinate (14e). To a CH2Cl2 solution (3 mL) of 10 (20 mg, 
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0.084 mmol) were added Boc2Leu2OH (16 mg, 0.06 mmol), DCC (16 mg, 0.06 
mmol) and DMAP (1 mg, 0.01 mmol). After stirring for 17 h, the reaction mixture 
was diluted with CH2Cl2 and washed with water and brine, dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the 
acylated 32benzyl2chroman242one (14e) (30 mg, 61 %). 1H2NMR (600 MHz, 
CDCl3) δ 7.07 (dd, 1H, J = 8.4 and 1.8 Hz), 6.93 (s, 1H), 6.90 (d, 1H, J =8.4 Hz), 
6.24 (s, 1H), 4.98 (d, 1H, J = 7.2 Hz), 4.57 (m, 1H), 4.28 (dd, 1H, J = 11.4 and 4.2 
Hz), 4.11 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.80 (s, 3H), 3.78 (s, 3H), 3.19 (dd, 
1H, J = 13.8 and 4.2 Hz), 2.74 (m, 1H), 2.65 (m, 1H), 1.87 (m, 2H), 1.65 (m, 1H), 
1.46 (s, 9H), 1.01 (s, 3H), 1.00 (s, 3H); 13C2NMR (150 MHz, CDCl3) δ 191.0, 
171.5, 159.7, 159.3, 155.3, 154.4, 149.6, 139.4, 137.5, 131.0, 127.5, 123.4, 112.6, 
108.6, 96.0, 79.9, 68.9, 61.6, 61.3, 56.1, 55.9, 52.2, 48.2, 41.9, 31.8, 28.3, 24.8, 
22.9; HRMS (FAB): mass calcd for C31H41NO10 [M + H
+], 588.2730; found, 
588.2810. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl (2S)-
2-((tert-butoxycarbonyl)amino)-4-phenylbutanoate (14f). To a CH2Cl2 solution 
(3 mL) of 10 (27 mg, 0.07 mmol) were added N2(tert2butoxycarbonyl)2l2
homophenylalanine (25 mg, 0.08 mmol), EDCI (14 mg, 0.08 mmol) and DMAP (2 
mg, 0.01 mmol). After stirring for 17 h, the reaction mixture was diluted with 
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CH2Cl2 and washed with water and brine, dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography 
on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the acylated 32benzyl2
chroman242one (14f) (31 mg, 67 %). 1H2NMR (600 MHz, CDCl3) δ 7.28 (m, 2H), 
7.21 (m, 3H), 7.06 (d, 1H, J = 8.4 Hz), 6.89 (d, 1H, J = 8.4 Hz) 4.63 (m, 1H), 4.26 
(dd, 1H, J = 11.4 and 4.2 Hz), 4.09 (m, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.78 (s, 
3H), 3.75 (s, 3H), 3.17 (dd, 1H, J = 13.8 and 4.2 Hz), 2.81 (t, 2H, J = 8.4 Hz), 2.72 
(m, 1H), 2.63 (dd, 1H, J = 13.8 and 10.8 Hz), 2.32 (m, 1H), 2.15 (m, 1H), 1.45 (s, 
9H) ; 13C2NMR (150 MHz, CDCl3) δ 191.0, 159.7, 159.3, 154.4, 149.6, 139.3, 
137.5, 131.1, 128.5, 128.4, 127.6, 126.1, 123.4, 120.5, 112.6, 108.6, 96.0, 69.0, 
61.6, 61.3, 56.1, 56.0, 55.9, 55.8, 53.4, 48.2, 34.5, 31.8, 31.8, 31.4, 28.3; HRMS 
(EI): mass calcd for C35H41NO10 [M
+], 635.2730; found, 635.2733. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl 
((benzyloxy)carbonyl)-L-phenylalaninate (14g). To a CH2Cl2 solution (3 mL) of 
10 (36 mg, 0.09 mmol) were added N2carbobenzoxy2l2phenylalanine (35 mg, 0.11 
mmol), EDCI (18 mg, 0.11 mmol) and DMAP (3 mg, 0.01 mmol). After stirring 
for 17 h, the reaction mixture was diluted with CH2Cl2 and washed with water and 
brine, dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate : n2hexane = 1 
: 2) to afford the acylated 32benzyl2chroman242one (14g) (28 mg, 44 %). 1H2NMR 
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(600 MHz, CDCl3) δ 7.3227.24 (m, 10H), 7.06 (d, 1H, J = 7.8 Hz), 6.89 (d, 1H, J = 
8.4 Hz), 6.82 (bs, 1H), 6.23 (s, 1H), 5.28 (dd, 1H, J = 8.4 and 3.0 Hz), 5.09 (dd, 
2H, J = 6.0 and 3.0 Hz), 4.94 (dd, 1H, J = 13.8 and 6.0 Hz), 4.26 (dd, 1H, J = 11.4 
and 4.2 Hz), 4.06 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.79 (s, 3H), 3.77 (s, 3H), 
3.34 (dd, 1H, J = 13.8 and 5.4 Hz), 3.25 (dd, 1H, J = 13.8 and 6.6 Hz), 3.17 (dd, 
1H, J = 13.8 and 4.2 Hz), 2.7122.68 (m, 1H), 2.62 (t, 1H, J =12 Hz); 13C2NMR 
(150 MHz, CDCl3) δ 191.0, 159.7, 159.3, 154.4, 149.6, 139.3, 137.5, 131.1, 128.5, 
128.4, 127.6, 126.1, 123.4, 120.5, 112.6, 108.6, 96.0, 69.0, 61.6, 61.3, 56.1, 56.0, 
55.9, 55.8, 53.4, 48.2, 34.5, 31.8, 31.8, 31.4, 28.3; HRMS (EI): mass calcd for 
C37H37NO10 [M
+], 655.2417; found, 655.2419. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl 
(ethylcarbamoyl)-L-phenylalaninate (14h). To a CH2Cl2 solution (2 mL) of 10 
(16 mg, 0.04 mmol) were added (2S)222[(ethylcarbamoyl)amino]232
phenylpropanoic acid (10 mg, 0.04 mmol), EDCI (10 mg, 0.06 mmol) and DMAP 
(1 mg, 0.004 mmol). After stirring for 24h, the reaction mixture was diluted with 
CH2Cl2 and washed with water and brine, dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography 
on silica gel (ethyl acetate : n2hexane = 1 : 1) to afford the acylated 32benzyl2
chroman242one (14h) (15 mg, 56 %). 1H2NMR (600 MHz, CDCl3) δ 7.28(bs, 5H), 
7.05(d, 1H, J = 8.4Hz), 6.89(d, 1H, J = 8.4Hz), 6.82(d, 1H, J = 1.8Hz), 6.23(s, 
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1H), 5.06(dd, 1H, J = 13.2 and 6Hz), 4.25(dd, 1H, J = 10.2 and 3.6Hz), 4.05(m, 
1H), 3.90(s, 3H), 3.85(s, 3H), 3.78(s, 3H), 3.77(s, 3H), 3.0523.21(m, 2H), 3.14(d, 
3H, J = 9Hz), 2.69(m, 1H), 2.61(dd 1H, J = 13.8 and 10.8Hz), 1.06(t, 3H, J = 3Hz) 
; 13C2NMR (150 MHz, CDCl3) δ 191.1, 159.7, 159.3, 157.0, 154.4, 149.6, 149.6, 
139.2, 137.5, 136.2, 131.0, 129.7, 128.5, 127.6, 127.0, 123.5, 112.6, 108.6, 96.0, 
69.0, 61.6, 61.3, 56.1, 55.8, 53.7, 48.2, 38.4, 35.3, 31.8, 15.3; HRMS (FAB): mass 
calcd for C32H36N2O9 [M + H
+], 593.2421; found, 593.2506. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl 
(butylcarbamoyl)-L-phenylalaninate (14i). To a CH2Cl2 solution (2 mL) of 10 
(23 mg, 0.06 mmol) were added N2[(butylamino)carbonyl]2l2phenylalanine (16 mg, 
0.06 mmol), EDCI (13 mg, 0.09 mmol) and DMAP (2 mg, 0.01 mmol). After 
stirring for 15 h, the reaction mixture was diluted with CH2Cl2 and washed with 
water and brine, dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel (ethyl acetate : 
n2hexane = 1 : 1) to afford the acylated 32benzyl2chroman242one (14i) (18 mg, 49 
%). 1H2NMR (600 MHz, CDCl3) δ 7.2922.22 (m, 5H), 7.05 (d, 1H, J = 8.4 Hz), 
6.88 (d, 1H, J = 9 Hz), 6.81 (s, 1H), 6.23 (s, 1H), 5.0625.02 (m, 1H), 4.25 (dd, 1H, 
J = 11.4 and 4.2 Hz), 4.06 (dd, 1H, J = 11.4 and 7.2 Hz), 3.89 (s, 3H), 3.85 (s, 3H), 
3.78 (s, 3H), 3.76 (s, 3H), 3.27 (m, 1H ), 3.23 (dd, 1H, J = 13.8 and 5.4 Hz), 3.15 
(d, 1H, J = 13.8 Hz), 3.07 (s, 2H), 2.7022.67 (m, 1H), 2.61 (dd, 1H, J = 13.8 and 
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10.2 Hz), 1.39 (m, 2H), 1.27 (m,2H), 0.86 (t, 3H, J = 4.8 Hz); 13C2NMR (150 
MHz, CDCl3) δ 191.1, 159.7, 159.3, 157.2, 124.4, 151.8, 149.6, 139.2, 137.5, 
136.3, 131.0, 129.7, 128.4, 127.5, 126.9, 123.5, 112.6, 108.6, 96.0, 69.0, 61.6, 
61.2, 56.1, 55.8, 53.8, 48.2, 40.2, 38.4, 32.1, 31.8, 19.9, 13.7; HRMS (FAB): mass 
calcd for C34H40N2O9 [M + H
+], 621.2734; found, 621.2830. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl tosyl-
L-phenylalaninate (14j). To a CH2Cl2 solution (3 mL) of 10 (26 mg, 0.07 mmol) 
were added N2(p2toluenesulfonyl)2l2phenylalanine (27 mg, 0.08 mmol), EDCI (13 
mg, 0.08 mmol) and DMAP (2 mg, 0.01 mmol). After stirring for 17 h, the reaction 
mixture was diluted with CH2Cl2 and washed with water and brine, dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the 
acylated 32benzyl2chroman242one (14j) (24 mg, 51%). 1H2NMR (600 MHz, 
CDCl3) 7.66 (d, 2H, J = 7.8 Hz), 7.2627.20 (m, 7H), 7.04 (dt, 1H, J = 8.4 and 2.4 
Hz), 6.55(d, 1H, J = 1.8 Hz), 6.24 (s, 1H), 5.08 (dd, 1H, J = 9 and 5.4 Hz), 4.48 
(m, 1H), 4.25 (dd, 1H, J = 11.4 and 4.2 Hz), 4.05 (m, 1H), 3.91 (s, 3H), 3.86 (s, 
3H), 3.79 (s, 3H), 3.70 (s, 3H), 3.26 (dd, 1H, J = 7.8 and 5.4 Hz), 3.17 (m, 2H), 
2.69 (m, 1H), 2.60 (m, 1H), 2.38 (d, 3H, J = 7.2 Hz) ; 13C2NMR (150 MHz, 
CDCl3) δ 191.1, 159.7, 159.3, 157.0, 154.4, 149.6, 149.6, 139.2, 137.5, 136.2, 
131.0, 129.7, 128.5, 127.6, 127.0, 123.5, 112.6, 108.6, 96.0, 69.0, 61.6, 61.3, 56.1, 
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55.8, 53.7, 48.2, 38.4, 35.3, 31.8, 15.3; HRMS (EI): mass calcd for C36H37NO10S 
[M + H+], 675.2138; found, 675.2136. 
tert-Butyl ((2S)-1-((2-methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-
yl)methyl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (15a). To a 
CH2Cl2 solution (3 mL) of 12b (35 mg, 0.09 mmol) were added Boc2Phe2OH (27 
mg, 0.09 mmol), EDCI (17 mg, 0.1 mmol) and DMAP (3 mg, 0.01 mmol). After 
stirring for 17 h, the reaction mixture was diluted with CH2Cl2 and washed with 
water and brine, dried over anhydrous MgSO4 and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel 
(ethyl acetate : n2hexane = 1 : 2) to afford the acylated 32benzyl2chroman242one 
(15a) (24 mg, 42%). 1H2NMR (600 MHz, CDCl3) δ 8.20 (s, 1H), 8.08 (bs, 1H), 
7.28 (d, 2H, J = 7.2 Hz), 7.22(d, 3H, J = 7.2 Hz), 6.88 (d, 1H, J = 8.4 Hz), 6.74 (d, 
1H, J = 7.8 Hz), 6.23 (d, 1H, J = 1.2 Hz), 5.11 (bs, 1H), 4.48 (bs, 1H), 4.28 (dd, 
1H, J = 10.8 and 3.6 Hz), 4.11 (q, 1H, J = 7.2 Hz), 3.90 (s, 3H), 3.85 (s, 3H), 3.78 
(s, 1H), 3.71 (s, 3H), 3.21 (dd, 1H, J = 13.8 and 3.6 Hz), 3.12 (bs, 2H), 2.79 (m, 
1H), 2.61 (t, 1H, J = 12 Hz), 1.4 (s, 9H); 13C2NMR (150 MHz, CDCl3) δ 191.2, 
169.2, 159.7, 159.2, 155.3, 154.4, 146.7, 137.4, 136.5, 131.0, 129.2, 128.7, 127.0, 
126.9, 124.4, 120.3, 110.0, 108.7, 96.0, 69.1, 61.6, 61.3, 56.6, 56.0, 55.6, 48.3, 
48.3, 38.5, 32.2, 28.2; HRMS (ESI): mass calcd for C34H40N2O10 [M + H
+], 
621.2807; found, 621.2804. 
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tert-Butyl ((2S)-3-(4′′-(benzyloxy)phenyl)-1-((2-methoxy-5-((5′,6′,7′-
trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl)amino)-1-oxopropan-2-
yl)carbamate (15b). To a CH2Cl2 solution (6 mL) of 12b (35 mg, 0.09 mmol) 
were added Boc2Tyr(Bzl)2OH,(35 mg, 0.09 mmol), EDCI (18 mg, 0.1 mmol) and 
DMAP (2 mg, 0.01 mmol). After stirring for 17 h, the reaction mixture was diluted 
with CH2Cl2 and washed with water and brine, dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography 
on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the acylated 32benzyl2
chroman242one (15b) (50 mg, 72%).  1H2NMR (600 MHz, CDCl3) δ 8.22 (s, 1H), 
8.10 (bs, 1H), 7.41 (d, 2H, J = 7.8 Hz), 7.37 (t, 2H, J = 7.2 Hz), 7.31 (t, 1H, J = 7.2 
Hz), 7.16 (d, 2H, J = 8.4 Hz), 6.90 (d, 3H, J = 8.4 Hz), 6.75 (d, 1H, J = 7.8 Hz), 
6.24 (s, 1H), 5.01 (s, 2H), 4.46 (bs, 1H), 4.29 (dd, 1H, J = 10.8 and 3.6 Hz), 4.12 
(m, 1H), 3.92 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H), 3.73 (s, 3H), 3.23 (dd, 1H, J = 
14.4 and 3.6 Hz), 3.10 (m, 2H), 2.81 (m, 1H), 2.63 (m, 1H), 1.42 (s, 9H); 13C2NMR 
(150 MHz, CDCl3) δ 191.3, 169.4, 159.7, 159.2, 127.8, 154.4, 146.7, 137.4, 136.9, 
131.0, 130.3, 128.5, 127.9, 127.4, 127.0, 124.4, 120.3, 115.0, 110.0108.7, 96.0, 
70.0, 69.2, 69.2, 61.6, 61.3, 56.0, 55.6, 48.3, 48.3, 37.7, 32.2, 30.9, 29.7, 28.2; 
HRMS (FAB): mass calcd for C41H46N2O10 [M + H
+], 727.3152; found, 727.3241. 
tert-Butyl ((2S)-3-(4′′-(allyloxy)phenyl)-1-((2-methoxy-5-((5′,6′,7′-
trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl)amino)-1-oxopropan-2-
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yl)carbamate (15c). To a CH2Cl2 solution (3 mL) of 12b (35 mg, 0.09 mmol) 
were added Boc2Tyr(Bzl)2OH (27 mg, 0.10 mmol), EDCI (17 mg, 0.10 mmol) and 
DMAP (3 mg, 0.01 mmol). After stirring for 17 h, the reaction mixture was diluted 
with CH2Cl2 and washed with water and brine, dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography 
on silica gel (ethyl acetate : n2hexane = 1 : 2) to afford the acylated 32benzyl2
chroman242one (15c) (42 mg, 71%). 1H2NMR (600 MHz, CDCl3) δ 8.22 (d, 1H, J 
= 2.4 Hz), 8.07 (bs, 1H), 7.15 (d, 2H, J = 8.4 Hz), 6.90 (d, 1H, J = 8.4 Hz), 6.84 (d, 
2H, J = 7.2 Hz), 6.76 (d. 1H, J = 8.4 Hz), 6.25 (d, 1H, J = 1.2 Hz), 6.0625.99 (m, 
1H), 5.40 (dd, 1H, J = 17.4 and 1.8 Hz), 5.27 (dd, 1H, J = 10.8 and 1.2 Hz), 5.12 
(bs, 1H), 4.49 (dd, 2H, J = 5.4 and 1.2 Hz), 4.30 (dd, 1H, J = 11.4 and 3.6 Hz), 
4.13 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.81 (s, 3H), 3.74 (s, 3H), 3.24 (dd, 1H, J 
= 14.4 and 4.2 Hz), 3.10 (m, 1H), 3.06 (bs, 1H), 2.8122.75 (m, 1H), 2.63 (m, 1H), 
1.43 (s, 9H); HRMS (FAB): mass calcd for C37H44N2O10 [M+H
+], 677.2996; 
found, 677.3074.  
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Supporting Information Scheme 1. Synthesis of B-ring Modified 3-Benzylidene-5,6,7-
trimethoxychroman-4-ones (7m–7r). 
 
 
Reagents and conditions: (i) arylaldehydes (Ar-CHO), p-TsOH, benzene, reflux (47–78%). 
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Supporting Information Scheme 2. Synthesis of 3-Benzyl-5,6,7-trimethoxychroman-4-one 
(12a). 
 
 
Reagents and conditions: (i) cinnamoyl chloride, BF3·Et2O, 98%; (ii) H2, Pd/C, MeOH, rt, 
96%; (iii) aq HCHO, NaOH, 60 °C, 43%. 
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Supporting Information Table 1. Growth Inhibitory Activity (GI50, µM) of 5,6,7-
Trimethoxychroman-4-one (6b) and B-ring Modified 3-Benzylidene-4-chromanone 
Analogues (7m–7r).	  95% Confidence Interval Shown in Parentheses. 
 
Cpd HREC HUVEC 92-1 Y79 
 
>100 >100 >100 >100 
 
8.6 
(2.7 – 27) 
9.1 
(3.6 – 23) 
30 
(5.5 – 160) 
8.2 
(2.2 – 30) 
 
17 
(9.2 – 33) 
5.8 
(3.1 – 11) 
8.5 
(3.4 – 21) 
4.2 
(2.3 – 7.5) 
 
>100 >100 >100 >100 
 
26 
(9.9 – 67) 
10 
(3.2 – 31) 
31 
(5.7 – 167) 
18 
(7.3 – 44) 
 
91 
(45 –187) 
45 
(21 – 96) 
>100 >100 
 
17 
(4.7 – 59) 
 
9.1 
(2.9 – 28) 
 
>100 9.1 
(4.5 – 18) 
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Supporting Information Figure 1. Compound 14a inhibits proliferation of HRECs as 
measured by EdU incorporation assay. The nuclei of all cells are labeled with DAPI (blue) 
and actively dividing cells are labeled with EdU (pink). Error bars indicate SEM, n = 3, 
representative results from at least triplicate experiments. **** P<0.0001. Scale bars = 200 
µm. 
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Supporting Information Figure 2. Compound 14a does not induce apoptosis significantly, 
as evidenced by TUNEL assay. The nuclei of all cells are shown in blue (DAPI staining) and 
TUNEL+ cells undergoing apoptosis are shown in red. Error bars indicate SEM, n = 3, 
representative results from at least triplicate experiments. Scale bars = 200 µm. 
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Supporting Information Figure 3. Viability of HRECs is not significantly altered by 
compound 14a as monitored in Trypan blue exclusion assays. Error bars indicate SEM, n = 3, 
representative results from triplicate experiments.  
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Supporting Information Figure 4. (A) Compound 14a arrests HRECs at the G2/M phase of 
the cell cycle. HRECs were treated with the indicated concentrations of 14a for 48 hours and 
then stained with propidium iodide before flow cytometry analysis. (B) Quantitative analysis 
of the cell cycle progression data. Representative results from duplicate experiments. 
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Supporting Information Experimental Procedures 
 
(E)-5,6,7-Trimethoxy-3-(2′-nitrobenzylidene)chroman-4-one (7m). To a benzene solution (3 
mL) of 5,6,7-trimethoxychroman-4-one (6b) (50 mg, 0.21 mmol) were added 2-
nitrobenzaldehyde (31 mg, 0.21 mmol) and p-toluenesulfonic acid (4 mg, 0.02 mmol) at 0 °C. 
After refluxing for 12 h with a Dean–Stark apparatus, the reaction mixture was cooled and 
quenched with saturated NaHCO3. The reaction mixture was diluted with ethyl acetate (10 
mL × 3) and washed with water and the combined organic phases were dried over MgSO4, 
and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate:n-hexane = 1:1.5) to afford 3-benzylidene-5,6,7-
trimethoxychromanone (7m) (49 mg, 63%). 1H-NMR (600 MHz, CDCl3) δ 8.19 (d, 1H, J = 
14.4 Hz), 8.01 (s, 1H), 7.68 (t, 1H, J = 7.2 Hz), 7.56 (t, 1H, J = 7.2 Hz), 7.21 (d, 1H, J = 7.8 
Hz), 6.22 (s, 1H), 4.90 (d, 2H, J = 1.8 Hz), 3.98 (s, 3H), 3.86 (s, 3H), 3.81 (s, 3H). 13C-NMR 
(150 MHz, CDCl3) δ 178.8, 159.8, 159.6, 155.0, 148.0, 138.0, 133.5, 133.1, 132.7, 131.0, 
130.7, 129.7, 125.3, 110.4, 96.2, 67.0, 61.6, 61.3, 56.1. HRMS (EI): mass calcd for 
C19H17NO7 [M+], 371.1005; found, 371.1005.  
(E)-5,6,7-Trimethoxy-3-(4′-nitrobenzylidene)chroman-4-one (7n). To a benzene solution (2 
mL) of 5,6,7-trimethoxychroman-4-one (6b) (24 mg, 0.1 mmol) were added 4-
nitrobenzaldehyde (17 mg, 0.11 mmol) and p-toluenesulfonic acid (2 mg, 0.01 mmol) at 0 °C. 
After refluxing for 12 h with a Dean–Stark apparatus, the reaction mixture was cooled and 
quenched with saturated NaHCO3. The reaction mixture was diluted with ethyl acetate (10 
mL × 3) and washed with water and the combined organic phases were dried over MgSO4, 
and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate:n-hexane = 1:1) to afford 4-benzylidene-5,6,7-
trimethoxychromanone (7n) (19 mg, 52%). 1H-NMR (600 MHz, CDCl3) δ 8.30 (d, 2H, J = 
9.0 Hz), 7.82 (s, 1H), 7.44 (d, 2H, J = 8.4 Hz), 6.27 (s, 1H), 5.17 (d, 2H, J = 1.8 Hz), 3.99 (s, 
3H), 3.90 (s, 3H), 3.84 (s, 3H). 13C-NMR (150 MHz, CDCl3) δ 178.6, 159.8, 154.8, 147.6, 
141.1, 134.6, 133.3, 130.3, 123.9, 96.2, 67.1, 61.6, 61.3, 56.2, 31.6, 14.2, 14.1. HRMS (EI): 
mass calcd for C19H17NO7 [M+], 371.1005; found, 371.1002. 
(E)-3-(4′-Benzyloxybenzylidene)-5,6,7-trimethoxychroman-4-one (7o). To a benzene 
solution (2 mL) of 5,6,7-trimethoxychroman-4-one (6b) (24 mg, 0.10 mmol) were added 4-
benzyloxybenzaldehyde (23 mg, 0.11 mmol) and p-toluenesulfonic acid (5 mg, 0.025 mmol) 
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at 0 °C. After refluxing for 12 h with a Dean–Stark apparatus, the reaction mixture was 
cooled and quenched with saturated NaHCO3. The reaction mixture was diluted with ethyl 
acetate (10 mL × 3) and washed with water and the combined organic phases were dried over 
MgSO4, and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate:n-hexane = 1:1) to afford 4-benzylidene-5,6,7-
trimethoxychromanone (7o) (24 mg, 56%). 1H-NMR (600 MHz, CDCl3) δ 7.79 (s, 1H), 7.44 
(m, 5H), 7.25 (d, 2H, J = 9 Hz), 7.03 (d, 2H, J = 9 Hz), 6.26 (s, 1H), 5.23 (d, 2H, J = 1.8 Hz), 
5.11 (s, 2H), 3.98 (s, 3H), 3.88 (s, 3H), 3.83 (s, 3H). 13C-NMR (150 MHz, CDCl3) δ 179.6, 
160.0, 159.6, 159.3, 159.1, 154.7, 137.8, 136.4, 136.1, 131.8, 129.8, 128.7, 128.2, 127.5, 
115.0, 110.6, 96.1, 70.1, 67.6, 61.6, 61.3, 56.1. HRMS (EI): mass calcd for C26H24O6 [M+], 
432.1573; found, 432.1572. 
(E)-3-(2′,3′-Dichlorobenzylidene)-5,6,7-trimethoxychroman-4-one (7p). To a benzene 
solution (3 mL) of 5,6,7-trimethoxychroman-4-one (6b) (50 mg, 0.21 mmol) were added 2,3-
dichlorobenzaldehyde (37 mg, 0.21 mmol) and p-toluenesulfonic acid (5 mg, 0.02 mmol) at 0 
°C. After refluxing for 12 h with a Dean–Stark apparatus, the reaction mixture was cooled 
and quenched with saturated NaHCO3. The reaction mixture was diluted with ethyl acetate 
(10 mL × 3) and washed with water and the combined organic phases were dried over 
MgSO4, and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate:n-hexane = 1:1) to afford 4-benzylidene-5,6,7-
trimethoxychromanone (7p) (39 mg, 47%). 1H-NMR (600 MHz, CDCl3) δ 7.83 (s, 1H), 7.46 
(dd, 1H, J = 8.4 and 1.2 Hz), 7.23 (dd, 1H, J = 12.6 and 4.8 Hz), 6.98 (d, 1H, J = 8.4 Hz), 
6.23 (s, 1H), 4.97 (d, 2H, J = 1.2 Hz), 3.96 (s, 3H), 3.85 (s, 3H), 3.80 (s, 3H). 13C-NMR (150 
MHz, CDCl3) δ 178.9, 159.7, 159.6, 154.9, 138.0, 135.4, 133.9, 133.6, 133.0 ,132.9, 130.8, 
128.2, 127.0, 110.3, 96.2, 67.2, 61.6, 61.3, 56.1. HRMS (EI): mass calcd for C19H16Cl2O5 
[M+], 394.0375; found, 394.0378. 
(E)-5,6,7-Trimethoxy-3-(2′,3′,4′-trimethoxybenzylidene)chroman-4-one (7q). To a benzene 
solution (3 mL) of 5,6,7-trimethoxychroman-4-one (6b) (50 mg, 0.21 mmol) were added 
2,3,4-trimethoxybenzaldehyde (41 mg, 0.21 mmol) and p-toluenesulfonic acid (5 mg, 0.02 
mmol) at 0 °C. After refluxing for 12 h with a Dean–Stark apparatus, the reaction mixture 
was cooled and quenched with saturated NaHCO3. The reaction mixture was diluted with 
ethyl acetate (10 mL × 3) and washed with water and the combined organic phases were dried 
over MgSO4, and concentrated under reduced pressure. The residue was purified by flash 
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column chromatography on silica gel (ethyl acetate:n-hexane = 1:5) to afford 4-benzylidene-
5,6,7-trimethoxychromanone (7q) (68 mg, 78%). 1H-NMR (600 MHz, CDCl3) δ 7.83 (s, 1H), 
6.74 (d, 1H, J = 8.4 Hz), 6.59 (d, 1H, J = 8.4 Hz), 6.19 (s, 1H), 5.04 (d, 2H, J = 1.8 Hz), 3.94 
(s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.79 (s, 3H), 3.77 (s, 3H).  13C-NMR (150 
MHz, CDCl3) δ 179.7, 159.5, 159.1, 155.0, 154.7, 153.0, 142.4, 137.7, 132.2, 130.8, 125.1, 
121.7, 110.6, 106.9, 96.1, 68.1, 61.6, 61.4, 61.2, 60.9, 56.1, 56.0. HRMS (EI): mass calcd for 
C22H24O8 [M+], 416.1471; found, 416.1467. 
(E)-5,6,7-Trimethoxy-3-(3′,4′,5′-trimethoxybenzylidene)chroman-4-one (7r). To a benzene 
solution (3 mL) of 5,6,7-trimethoxychroman-4-one (6b) (100 mg, 0.42 mmol) were added 
3,4,5-trimethoxybenzaldehyde (82 mg, 0.42 mmol) and p-toluenesulfonic acid (9 mg, 0.04 
mmol) at 0 °C. After refluxing for 12 h with a Dean–Stark apparatus, the reaction mixture 
was cooled and quenched with saturated NaHCO3. The reaction mixture was diluted with 
ethyl acetate (10 mL × 3) and washed with water and the combined organic phases were dried 
over MgSO4, and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (ethyl acetate:n-hexane = 1:5) to afford 4-benzylidene-
5,6,7-trimethoxychromanone (7r) (130 mg, 75%). 1H-NMR (600 MHz, CDCl3) δ 7.65 (s, 
1H), 6.41 (s, 1H), 6.16 (s, 1H), 5.16 (s, 2H), 3.89 (s, 3H), 3.80 (s, 12H), 3.75 (s, 3H). 13C-
NMR (150 MHz, CDCl3) δ 179.2, 159.3, 159.2, 154.7, 153.1, 139.1, 137.8, 136.3, 131.1, 
130.1, 110.4, 107.2, 96.1, 67.5, 61.5, 61.2, 60.9, 56.1, 56.1. HRMS (EI): mass calcd for 
C22H24O8 [M+], 416.1471; found, 416.1465. 
3-Benzyl-5,6,7-trimethoxychroman-4-one (12a). To 3,4,5-trimethoxyphenol (184 mg, 1 
mmol) was added cinnamoyl chloride (199 mg, 1.2 mmol). To the reaction mixture was 
added BF3·Et2O (1 mL) at 0 °C, then refluxed at 120 °C for 4 h, followed by concentration in 
vacuo. The residue was purified by silica gel column chromatography (ethyl acetate:n-hexane 
= 1:2) to afford the chalcone 12a′ (309 mg, 98%). 1H-NMR  (400 MHz, CDCl3) δ 13.67 (1H, 
d, J = 6.36), 7.96 (1H, s), 7.83 (1H, s), 7.61 (2H, s), 7.39 (3H, m), 6.28 (1H, s), 3.91 (3H, s), 
3.88 (3H, s), 3.81 (3H, s). 13C-NMR (100 MHz, CDCl3) δ 192.9, 162.7, 160.1, 155.0, 143.2, 
135.3, 130.2, 128.9, 128.4, 126.5, 108.7, 96.5, 62.9, 61.2, 56.1. A solution of chalcone 12a′ 
(102 mg, 0.32 mmol) and 10% Pd/C (16 mg) in absolute EtOH (3 mL) was placed under an 
atmosphere of hydrogen. After stirring for 4 h, the reaction mixture was diluted with ethyl 
acetate, filtered through a short pad of silica gel and concentrated in vacuo. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate:n-hexane = 1:1) to 
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afford the dihydrochalcone (12a′′) (115 mg, 96%). 1H-NMR (400 MHz, CDCl3) δ 13.33 (s, 
1H), 7.21 (m, 4H), 7.18 (s, 1H), 6.17 (s, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 3.69 (s, 3H), 3.31 (m, 
2H), 2.97 (d, 2H, J = 7.8 Hz). 13C-NMR (100 MHz, CDCl3) δ 204.7, 161.8, 159.9, 155.0, 
141.4, 134.7, 128.4, 125.9, 108.2, 96.1, 61.0, 60.9, 56.0, 44.7, 30.4. IR (neat) vmax 2960, 
2924, 2852 cm-1. LRMS (ESI) m/z 317 [M+H+]. The dihydrochalcone (12a′′) (100 mg, 0.31 
mmol) was dissolved in 50 % aqueous NaOH (2 mL), H2O (6 mL) and stirred with formalin 
(0.04 mL, 1.61 mmol) at 60 °C for 3 h. After stirring for 3 h, the reaction mixture was diluted 
with ethyl acetate and washed with sat. NH4Cl and brine, dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate:n-hexane = 1:4) to afford 12a (44 mg, 43%). 1H-
NMR (400 MHz, CDCl3) δ 7.29 (m, 2H), 7.22 (m, 3H), 6.23 (s, 1H), 4.24 (d, 1H, J = 4.4 Hz), 
4.09 (d, 1H, J = 8.0 Hz), 3.91 (s, 3H), 3.86 (s, 3H), 3.79 (s, 3H), 3.27 (dd, 1H, J = 14.4 and 
4.0 Hz), 2.76 (m, 1H), 2.68 (dd, 1H, J = 10.2 and 4.8 Hz). 13C-NMR (100 MHz, CDCl3) δ 
191.1, 159.6, 159.2, 154.4, 138.5, 137.4, 129.1, 128.6, 126.5, 108.6, 95.9, 69.0, 61.5, 61.3, 
56.0, 48.2, 32.7. HRMS (EI): mass calcd for C19H20O5 [M+], 328.1311; found, 328.1312.   
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Supporting Information Table 2. Purity and Peak Attributions of the Homoisoflavonoid 
Analogues. 
 
Compounds 
Retention 
time 
(min) 
Purity 
(area %) Compounds 
Retention 
time 
(min) 
Purity 
(area %) 
6b 0.58 98.8 12b 0.85 95.4 
7b 0.79 95.3 12c 0.92 98.0 
7c 0.73 96.6 12d 0.81 99.7 
7d 2.37 95.2 12e 2.11 98.6 
7e 1.53 95.1 12f 2.15 97.7 
7f 1.19 96.7 12g 3.25 96.9 
7g 1.02 97.5 12h 2.62 96.7 
7h 0.79 96.5 12i 1.88 95.9 
7i 0.79 95.1 14a 3.27 96.8 
7j 2.54 97.7 14b 7.18 96.7 
7k 0.62 98.5 14c 4.36 97.6 
7l 5.84 97.8 14d 3.55 99.1 
7m 1.09 97.3 14e 3.41 96.3 
7n 1.36 95.4 14f 4.12 95.6 
7o 3.24 96.0 14g 3.20 97.2 
7p 2.63 95.8 14h 1.14 96.6 
7q 1.26 95.8 14i 1.71 98.5 
7r 1.13 96.8 14j 2.83 97.9 
10 1.11 97.9 15a 2.42 98.5 
11 0.68 95.4 15b 0.55 98.1 
12a 1.40 99.3 15c 3.22 96.4 
 
HPLC conditions: 
System: Agilent 1260 infinity binary LC 
Detector: Agilent 1260 infinity UV detector, 256 nm 
Column: Waters Sunfire 5 µM 4.6 × 50 mm 
Sample diluent: 99.6 % methanol 
Mobile phase: 60% MeCN/Water 
Mode: Isocratic system 
Flow rate: 1.5 mL/min 
Injection volume: 20 µL 
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Biological Methods 
Materials 
EBM-2 and IMDM growth media were purchased from Lonza (Walkersville, MD, USA). 
RPMI and Ham’s/F-10 media were purchased from Thermo Scientific (Waltham, MA, USA). 
HRECs and Attachment Factor were purchased from Cell Systems (Kirkland, WA, USA). 
Clonetics® HUVECs were purchased from Lonza. All endothelial cells were used between 
passages 5 and 8. Endothelial Growth Medium (EGM-2) was prepared by mixing the 
contents of an EGM-2 “Bullet Kit” (Cat. no. CC-4176) with Endothelial Basal Medium 
(EBM) (Lonza). The EGM-2 “Bullet Kit” contains hydrocortisone, human fibroblast growth 
factor (hFGF), VEGF, R3-insulin like growth factor (R3-IGF-1), ascorbic acid, human 
epidermal growth factor (hEGF), gentamycin and heparin along with 2% fetal bovine serum 
(FBS). 92-1 cells1 (a kind gift from Dr. Martine Jager) were grown in RPMI medium 
containing 10% FBS and 1% penicillin-streptomycin (pen-strep). Y79 cells2 (a kind gift from 
Dr. Brenda Gallie) were grown in RB medium (IMDM + 10% FBS + 55 µM β-
mercaptoethanol + 10 µg/mL Insulin + 1% pen-strep). Identity of 92-1 and Y79 cell lines was 
confirmed by short tandem repeat profiling. Click-iT TUNEL Alexa Fluor-594 imaging assay 
kit (Cat. no. C10246) was purchased from Molecular Probes (Eugene, OR, USA). 
Cell Proliferation Assay 
The proliferation of cells was monitored by an alamarBlue based fluorescence assay as 
described previously.3 Four cell types were used: HRECs, HUVECs, 92-1, and Y79. Briefly, 
2,500 cells in 100 µL growth medium were incubated in 96-well clear bottom black plates for 
24 hours followed by 48 hours’ incubation with different concentrations of each test 
compound (range: 0.5 nM to 500 µM). At the end of the incubation, 11.1 µL of alamarBlue 
reagent was added and 4 hours after, fluorescence readings were taken with excitation and 
emission wavelengths of 560 nm and 590 nm respectively. Data were analyzed and dose 
response curves generated using GraphPad Prism software (v. 6.0). Only those compounds 
that reduced cell number by 50% or more at the highest concentration tested (relative to 
DMSO control) were reported as having a GI50 < 100 µM. 
EdU Incorporation Assay 
The assay was carried out as described before.3 HRECs (25,000) were seeded onto coverslips 
coated with attachment factor and grown for 24 hours before starving in serum-free EBM-2 
medium. After starvation for 12 hours, the cells were incubated with 10 µM EdU in the 
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presence of various concentrations of 14a for 8 hours. Then the cells were processed 
according to the manufacturer’s instructions for the click-iT EdU assay kit (Life 
Technologies, Grand Island, NY, USA). The images were taken using an EVOS-fl digital 
microscope (AMG, Mill Creek, WA, USA) and data were analyzed using ImageJ software v. 
1.48V (http://imagej.nih.gov/ij/). 
Cell Viability Assay 
HRECs were grown in complete EGM-2 medium in a 6-well plate to 70 % confluency and 
then incubated with different concentrations of 14a for 48 hours. After the incubation and 
trypsinization, the number of live and dead cells were counted in each well (including 
floating cells in the medium) using Trypan blue dye and a hemocytometer. The percentage of 
viable cells was calculated as the ratio of the number of live cells to the total number of cells 
(sum of live and dead cells). The resulting data were analyzed in GraphPad Prism software (v. 
6.0). 
Cell Cycle Analysis 
HRECs were grown in complete EGM-2 medium in a 10 cm plate until 50 % confluency was 
reached and then the cells were serum starved overnight. The medium was replaced with 
fresh EGM-2 medium containing different concentrations of 14a. After 48 hours of 
incubation, cells were washed twice in ice-cold PBS, trypsinized and collected in 1.5 mL 
tubes. Cells were fixed in 66 % EtOH solution for 2 hours at 4 °C. After the fixation, the cells 
were washed twice in ice-cold PBS. Fixed cells were resuspended in 300 µL of propidium 
iodide staining solution (20 µg/mL propidium iodide solution prepared in 0.1 % (v/v) Triton 
X-100 in PBS and 1× RNase [Qiagen]). Cells were incubated at 37 °C for 30 min before 
analysis by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA). Cell cycle 
profiles were then generated using FlowJo software (v. 10). 
Apoptosis Assays 
Caspase-3 Immunofluorescence Assay: The assay was carried out as described previously.3 
Briefly, cells were plated on coated coverslips and incubated in EGM-2 medium overnight 
before treating with indicated concentrations of 14a. After 4 hours of compound treatment the 
cells were fixed in 4% paraformaldehyde and permeabilized using 0.5 % Triton X-100 
solutions prepared in PBS. Then cells were immunostained using an antibody against 
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activated caspase 3 (9661S, Cell Signaling, Beverly, MA, USA) and imaged using an LSM 
700 confocal microscope (Zeiss, Thornwood, NY, USA). 
TUNEL Assay: Cells (25,000 per coverslip) were seeded on each coverslip coated with 
attachment factor in a 6-well plate and grown overnight in EGM-2 medium. Next day, fresh 
medium with the indicated concentrations of 14a was added to cells and they were incubated 
for 4 hours. Cells were then fixed in 4 % paraformaldehyde prepared in PBS for 20 min at 
room temperature. The coverslips were washed twice in PBS and incubated further for 20 
min in 0.25 % Triton X-100 in PBS.  Then coverslips were washed in PBS twice and 
apoptotic cells were visualized using the Click-iT TUNEL assay kit as per the manufacturer’s 
instructions, with DAPI counter-stain. The percentage of apoptotic cells was counted on three 
low-power fields per coverslip using Image J software and analyzed using GraphPad Prism 
software (v. 6.0). 
In Vitro Scratch-Wound Assay 
HRECs (105) were seeded in each well of a 6-well plate coated with attachment factor. The 
cells were incubated in EGM-2 medium until confluent (~24 hours). The cells were then 
starved for 12 hours in serum free EBM-2 medium. After starvation, a straight scratch was 
introduced in the well with a sterile fine 10 µL micropipette tip. The well was rinsed twice 
with EBM-2 medium to remove unbound cells and debris and the well was imaged at time = 
0. Then cells were incubated in EGM-2 medium in the presence of the indicated 
concentrations of 14a at 37°C and 5% CO2. After 8 hours, images were taken using the 
EVOS microscope and the number of migrated cells into the scratched area was counted. 
In Vitro Angiogenesis Assay 
A Matrigel based assay was performed to monitor the tube formation ability of HRECs in the 
presence of 14a as described previously.3 Briefly, 7,500 cells in 100 µL EGM-2 medium 
were incubated in the presence or absence of 14a in 96-well clear plates coated with 50 µL of 
Matrigel basement membrane. After 8 hours, the images were recorded using the EVOS 
microscope and the tube length was measured using angiogenesis analyzer macros in ImageJ 
(http://image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-ImageJ). 
Oxygen Induced Retinopathy (OIR) Mouse Model 
All animal experiments were approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee and adhered to all standards set forth in the 
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Association for Research in Vision and Ophthalmology Statement for the Use of Animals in 
Ophthalmic and Vision Research. OIR in mice was induced as described.4 Briefly, newborn 
C57BL/6 mice pups along with nursing mother were incubated in a hyperoxia chamber (75% 
O2) from postnatal day (P)7 to P12. On day P12, pups were anesthetized using isoflurane and 
vehicle/anti-VEGF/14a was intravitreously injected into each eye under a dissecting 
microscope. The clogP of 14a is 4.64. It dissolved readily in DMSO up to 100 mM and was 
then diluted into phosphate-buffered saline solution up to 50 µM (final [DMSO] = 0.02%). 
By injecting 0.5 µL of a 10 µM aqueous solution of 14a, we estimate a final intravitreal 
concentration of 1 µM, based on the average vitreous volume of young mice of 4.6 µL.5 For 
control experiments, a total of 5 ng of anti-VEGF antibody in 0.5 µL vehicle, or 0.5 µL 
vehicle alone, was delivered to the vitreous. The experimenters (HDB, GR, and AV) were 
masked to the identity of the treatments throughout experimentation and data analysis.  
After the injections, pups along with the nursing mother were returned to normoxia (room 
air) conditions from P12 to P17. On day P17, pups were killed and the eyes were enucleated 
and fixed in 4 % paraformaldehyde for 4 hours. Then retinas were isolated under a dissecting 
microscope. Retinas were washed twice in PBS and then permeabilized for 2 hours in 0.1 % 
Triton X-100 in 10 % goat serum prepared in PBS. Then 1:200 diluted isolectin B4-Alexa 
488 in 10% goat serum was added to each retina and incubated overnight at room 
temperature protected from light. After the incubation, retinas were washed 4 times in PBS 
with each wash lasting for 15 minutes. Retinas were incised into four sections on a glass slide 
and mounted using Vectashield mounting medium. Using the LSM700 confocal microscope, 
approximately 20 images were taken for each retina with a 10× objective and all of these 
images were stitched using Adobe Photoshop CS5. Retinal neovascularization was quantified 
as described6 using Adobe Photoshop CS5 software. 
Statistical Analysis 
The data obtained from all experiments were analyzed by one-way ANOVA with Dunnett’s 
post hoc tests for comparisons between compound treatments and control. All analyses were 
performed using GraphPad Prism software (v. 6.0). A P value of < 0.05 was considered 
statistically significant in all tests.  
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